<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001480.pub4" GROUP_ID="ARI" ID="180999081614140532" MERGED_FROM="" MODIFIED="2014-03-24 21:30:10 +0000" MODIFIED_BY="Liz Dooley" REVIEW_NO="A051" REVMAN_SUB_VERSION="5.2.8 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2014-03-24 21:30:10 +0000" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2008-04-29 01:11:33 +1000" MODIFIED_BY="[Empty name]">Pneumococcal conjugate vaccines for preventing otitis media</TITLE>
<CONTACT MODIFIED="2014-03-24 21:30:10 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="17260" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roger</FIRST_NAME><MIDDLE_INITIALS>AMJ</MIDDLE_INITIALS><LAST_NAME>Damoiseaux</LAST_NAME><SUFFIX>PhD</SUFFIX><EMAIL_1>R.A.M.J.Damoiseaux@umcutrecht.nl</EMAIL_1><EMAIL_2>rdamoiseaux@hotmail.com, R.DAMOISEAUX@tiscali.nl</EMAIL_2><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>HP: Str. 6.131</ADDRESS_1><ADDRESS_2>PO Box 85500</ADDRESS_2><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-03-24 21:30:10 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="z1301092144247893196943259445818" ROLE="AUTHOR"><FIRST_NAME>Alexandre</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Fortanier</LAST_NAME><POSITION>PhD student</POSITION><EMAIL_1>a.c.fortanier@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>HP: Str. 6.131</ADDRESS_1><ADDRESS_2>PO Box 85500</ADDRESS_2><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="12462205442426823266100401013025" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roderick</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Venekamp</LAST_NAME><POSITION>Postdoctoral researcher and GP trainee</POSITION><EMAIL_1>R.P.Venekamp@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Otorhinolaryngology &amp; Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 7555100</PHONE_1><FAX_1>+31 88 7568099</FAX_1></ADDRESS></PERSON><PERSON ID="85ADAAD282E26AA20053879371EFE61C" ROLE="AUTHOR"><FIRST_NAME>Chantal</FIRST_NAME><MIDDLE_INITIALS>WB</MIDDLE_INITIALS><LAST_NAME>Boonacker</LAST_NAME><EMAIL_1>C.W.B.Boonacker@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="19944" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Eelko</FIRST_NAME><LAST_NAME>Hak</LAST_NAME><SUFFIX>MSc, PhD</SUFFIX><POSITION>Associate Professor of Clinical Epidemiology of Infectious Diseases</POSITION><EMAIL_1>e.hak@rug.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>University Medical Center Groningen</ORGANISATION><ADDRESS_1>Hanzeplein 1</ADDRESS_1><ADDRESS_2>PO Box 30.001</ADDRESS_2><CITY>Groningen</CITY><ZIP>9700 RB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 756 8214</PHONE_1><FAX_1>+31 88 756 8099</FAX_1></ADDRESS></PERSON><PERSON ID="8534" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anne</FIRST_NAME><MIDDLE_INITIALS>GM</MIDDLE_INITIALS><LAST_NAME>Schilder</LAST_NAME><EMAIL_1>A.Schilder@umcutrecht.nl</EMAIL_1><EMAIL_2>a.schilder@ucl.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>evidENT, Ear Institute</DEPARTMENT><ORGANISATION>Faculty of Brain Sciences, University College London</ORGANISATION><ADDRESS_1>330 Grays Inn Road</ADDRESS_1><CITY>London</CITY><ZIP>WC1X 8DA</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="AAD1CC6F82E26AA20130726F1B467FE4" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Elisabeth</FIRST_NAME><MIDDLE_INITIALS>AM</MIDDLE_INITIALS><LAST_NAME>Sanders</LAST_NAME><EMAIL_1>L.Sanders@umcutrecht.nl</EMAIL_1><EMAIL_2>l.sanders@wkz.azu.nl</EMAIL_2><ADDRESS><DEPARTMENT>Department of Pediatric Immunology and Infectious Diseases</DEPARTMENT><ORGANISATION>Wilhelmina Children's Hospital, University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85090</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 AB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 2504349</PHONE_1></ADDRESS></PERSON><PERSON ID="17260" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roger</FIRST_NAME><MIDDLE_INITIALS>AMJ</MIDDLE_INITIALS><LAST_NAME>Damoiseaux</LAST_NAME><SUFFIX>PhD</SUFFIX><EMAIL_1>R.A.M.J.Damoiseaux@umcutrecht.nl</EMAIL_1><EMAIL_2>rdamoiseaux@hotmail.com, R.DAMOISEAUX@tiscali.nl</EMAIL_2><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>HP: Str. 6.131</ADDRESS_1><ADDRESS_2>PO Box 85500</ADDRESS_2><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-12-09 10:15:43 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="3" MONTH="12" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="12" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="12" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-03-21 01:25:26 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-03-21 01:23:58 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="2" YEAR="2014"/>
<DESCRIPTION>
<P>With this update, more precise information on the effect of PCV7 for the prevention of otitis media has become available. We judged the quality of the evidence for PCV7 in both early infancy and older children to be high and further research is very unlikely to change our confidence in the estimate of effect.</P>
<P>Based on current evidence of the effects of pneumococcal conjugate vaccines (PCVs) for preventing acute otitis media (AOM), the licensed 7-valent PCV has modest beneficial effects in healthy infants with a low baseline risk of AOM. Administering PCV7 in high-risk infants, after early infancy and in older children with a history of AOM appears to have no benefit in preventing further episodes.</P>
<P>Currently, several randomised controlled trials (RCTs), with different (newly licensed, multivalent) PCVs administered during early infancy, are ongoing to establish their effects on AOM. The results of these studies may provide a better understanding of the role of the newly licensed, multivalent PCVs in preventing AOM. Also the impact of the carrier protein D, as used in certain pneumococcal vaccines for AOM, needs to be further established.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-21 01:25:26 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>Three new review authors joined the team to update this review.</P>
<P>With the updated search (November 2007 to December 2013) we retrieved 171 records. Removing duplicates left 165 records. After screening titles and abstracts, three new publications remained for inclusion (<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>). One study was an additional analysis of the previously included <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> study.</P>
<P>We identified five 'ongoing' RCTs (<LINK REF="STD-NCT00466947" TYPE="STUDY">NCT00466947</LINK>; <LINK REF="STD-NCT00861380" TYPE="STUDY">NCT00861380</LINK>; <LINK REF="STD-NCT01545375" TYPE="STUDY">NCT01545375</LINK>; <LINK REF="STD-NCT01735084" TYPE="STUDY">NCT01735084</LINK>; <LINK REF="STD-NCT01174849" TYPE="STUDY">NCT01174849</LINK>).</P>
<P>The 11 included studies in this review concerned nine RCTs in total: (1) <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; (2) <LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>; (3) <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; (4) <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; (5) <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>; (6) <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; (7) <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>; (8) <LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK> and (9) <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>. Five trials (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>) (n = 47,108) included healthy infants and studied the effect of PCV administered in early infancy on otitis media (OM), while the other four trials (n = 1318) (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>; <LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>) assessed the effects of PCV administered at a later age on OM in either healthy infants (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>) or in children with a known history of respiratory disease, including OM (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>New review authors</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-01-21 09:44:20 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="28" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-09-09 11:06:38 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="15" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Searches conducted</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="26" MONTH="11" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-20 10:48:14 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="29" MONTH="6" YEAR="2003"/>
<DESCRIPTION>
<P>Searches conducted</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-20 10:46:38 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="19" MONTH="8" YEAR="2000"/>
<DESCRIPTION>
<P>Searches conducted</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-11-15 21:17:28 +1000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-11-15 21:17:28 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-04-29 23:26:52 +1000" MODIFIED_BY="[Empty name]">
<NAME>Department of Pediatric Immunology and Infectious Diseases, UMC Utrecht, Wilhelmina Children's Hospital Utrecht</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-04-29 23:27:54 +1000" MODIFIED_BY="[Empty name]">
<NAME>Julius Center for Health Sciences and Primary Care, UMC Utrecht, the Netherlands</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-04-29 23:27:50 +1000" MODIFIED_BY="[Empty name]">
<NAME>Department of Otorhinolaryngology, UMC Utrecht, Wilhelmina Children's Hospital Utrecht</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-11-15 21:17:28 +1000" MODIFIED_BY="[Empty name]">
<NAME>University Center for Pharmacy, PharmacoEpidemiology &amp; PharmacoEconomics, University of Groningen</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-03-24 21:47:41 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-03-21 21:18:27 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-11-15 07:33:06 +1000" MODIFIED_BY="Liz Dooley">Vaccination against a bacterium called pneumococcus for preventing middle ear infection</TITLE>
<SUMMARY_BODY MODIFIED="2014-03-21 21:18:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
<BR/>We reviewed the evidence about the effect of vaccination against pneumococcus (a type of bacterium) on preventing middle ear infections in children.</P>
<P>
<B>Background</B>
<BR/>Middle ear infection, or otitis media, is one of the most common respiratory infections in childhood. Infection with <I>Streptococcus pneumoniae</I> (pneumococcus) is a frequent cause of middle ear infection. Vaccination against pneumococcus with pneumococcal conjugate vaccines (PCVs) is primarily introduced to protect young children against severe pneumococcal infections, such as meningitis and pneumonia. We wanted to discover whether vaccination with PCV also leads to fewer middle ear infections in children.</P>
<P>
<B>Study characteristics</B>
<BR/>This review included evidence up to 3 December 2013. Nine trials with a total of 48,426 children were included; five trials included 47,108 infants, while four trials included 1318 children at a later age, i.e. aged one to seven years, who were either healthy (one trial, 264 children) or had previous upper respiratory tract infections, including middle ear infections. All trials had a long follow-up, varying from 6 to 40 months.</P>
<P>
<B>Key outcomes</B>
<BR/>When vaccinating against seven different serotypes of pneumococcus (7-valent PCV) during early infancy, the occurrence of middle ear infections either increased by 5% or decreased by 6% to 7%. One study in infants used 11 serotypes of pneumococcus together with a carrier protein from another bacterium (<I>Haemophilus influenzae</I>); this decreased the occurrence of middle ear infections by 34%.</P>
<P>Children with a history of middle ear infections do not seem to benefit from 7-valent PCV when immunised at an older age (after infancy).</P>
<P>
<B>Quality of the evidence</B>
<BR/>We judged the quality of the evidence for 7-valent PCV in early infancy to be high (further research is very unlikely to change our confidence in the estimate of effect), while we judged the quality of the evidence for multivalent (more than seven different serotypes) PCV to be moderate (further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate), as this evidence is derived from only one trial. We judged the quality of the evidence for 7-valent PCV in older children with a history of middle ear infections to be high.</P>
<P>Future studies on the effects of PCV in infants, with broader serotype coverage (more than seven different serotypes), are likely to provide more understanding of the role of PCV in preventing middle ear infections.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-03-24 21:47:41 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Acute otitis media (AOM) is a very common respiratory infection in early infancy and childhood. The marginal benefits of antibiotics for AOM in low-risk populations in general, the increasing problem of bacterial resistance to antibiotics and the huge estimated direct and indirect annual costs associated with otitis media (OM) have prompted a search for effective vaccines to prevent AOM.<BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-02-08 01:29:17 +1000" MODIFIED_BY="Liz Dooley">
<P>To assess the effect of pneumococcal conjugate vaccines (PCVs) in preventing AOM in children up to 12 years of age.<BR/>
</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2013, Issue 11), MEDLINE (1995 to November week 3, 2013), EMBASE (1995 to December 2013), CINAHL (2007 to December 2013), LILACS (2007 to December 2013) and Web of Science (2007 to December 2013).<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-11-27 14:34:53 +1000" MODIFIED_BY="Liz Dooley">
<P>Randomised controlled trials (RCTs) of PCVs to prevent AOM in children aged 12 years or younger, with a follow-up of at least six months after vaccination.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-11-15 07:33:06 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed trial quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-03-21 01:26:33 +1000" MODIFIED_BY="[Empty name]">
<P>We included 11 publications of nine RCTs (n = 48,426 children, range 74 to 37,868 per study) of 7- to 11-valent PCV (with different carrier proteins). Five trials (n = 47,108) included infants, while four trials (n = 1318) included children aged one to seven years that were either healthy (one study, n = 264) or had a previous history of upper respiratory tract infection (URTI), including AOM. We judged the methodological quality of the included studies to be moderate to high. There was considerable clinical diversity between studies in terms of study population, type of conjugate vaccine and outcome measures. We therefore refrained from pooling the results.</P>
<P>In three studies, the 7-valent PCV with CRM197 as carrier protein (CRM197-PCV7) administered during early infancy was associated with a relative risk reduction (RRR) of all-cause AOM ranging from -5% in high-risk children (95% confidence interval (CI) -25% to 12%) to 7% in low-risk children (95% CI 4% to 9%). Another 7-valent PCV with the outer membrane protein complex of <I>Neisseria meningitidis </I>(<I>N. meningitidis</I>) serogroup B as carrier protein, administered in infancy, did not reduce overall AOM episodes, while a precursor 11-valent PCV with <I>Haemophilus influenzae</I> (<I>H. influenzae</I>) protein D as carrier protein was associated with a RRR of all-cause AOM episodes of 34% (95% CI 21% to 44%).</P>
<P>A 9-valent PCV (with CRM197 carrier protein) administered in healthy toddlers was associated with a RRR of (parent-reported) OM episodes of 17% (95% CI -2% to 33%). CRM197-PCV7 followed by 23-valent pneumococcal polysaccharide vaccination administered after infancy in older children with a history of AOM showed no beneficial effect on first occurrence and later AOM episodes. In a study in older children with a previously diagnosed respiratory tract infection, performed during the influenza season, a trivalent influenza vaccine combined with placebo (TIV/placebo) led to fewer all-cause AOM episodes than vaccination with TIV and PCV7 (TIV/PCV7) when compared to hepatitis B vaccination and placebo (HBV/placebo) (RRR 71%, 95% CI 30% to 88% versus RRR 57%, 95% CI 6% to 80%, respectively) indicating that CRM197-PCV7 after infancy may even have negative effects on AOM.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-03-24 21:47:41 +1000" MODIFIED_BY="[Empty name]">
<P>Based on current evidence of the effects of PCVs for preventing AOM, the licensed 7-valent CRM197-PCV7 has modest beneficial effects in healthy infants with a low baseline risk of AOM. Administering PCV7 in high-risk infants, after early infancy and in older children with a history of AOM, appears to have no benefit in preventing further episodes. Currently, several RCTs with different (newly licensed, multivalent) PCVs administered during early infancy are ongoing to establish their effects on AOM. Results of these studies may provide a better understanding of the role of the newly licensed, multivalent PCVs in preventing AOM. Also the impact on AOM of the carrier protein D, as used in certain pneumococcal vaccines, needs to be further established.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-03-24 21:47:31 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-03-21 21:21:33 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Acute otitis media (AOM), defined as middle ear effusion accompanied by one or more signs of acute inflammation in the middle ear, such as otalgia, otorrhoea, fever or irritability, is one of the most common diseases in childhood, imposing a large burden on public health. It has a peak incidence in six to 11-month-old infants (<LINK REF="REF-Teele-1989" TYPE="REFERENCE">Teele 1989</LINK>). By the age of one year, approximately 60% of infants have experienced at least one AOM episode and by the age of two years up to 5% of all children have experienced recurrent episodes of AOM, defined as three or more AOM episodes in six months or four or more in one year (<LINK REF="REF-Kvaerner-1997" TYPE="REFERENCE">Kvaerner 1997</LINK>; <LINK REF="REF-Teele-1989" TYPE="REFERENCE">Teele 1989</LINK>). The three main bacterial pathogens isolated from the middle ear fluid of children with AOM, collected before the widespread use of pneumococcal conjugate vaccines (PCVs), were <I>Streptococcus pneumoniae</I> (<I>S. pneumoniae</I>) (25% to 39%), (non-typeable) <I>Haemophilus influenzae</I> (<I>H. influenzae</I>) (12% to 23%) and <I>Moraxella catarrhalis</I> (<I>M. catarrhalis</I>) (4% to 15%) (<LINK REF="REF-Bluestone-1992" TYPE="REFERENCE">Bluestone 1992</LINK>; <LINK REF="REF-Heikkinen-1999" TYPE="REFERENCE">Heikkinen 1999</LINK>; <LINK REF="REF-Jacobs-1998" TYPE="REFERENCE">Jacobs 1998</LINK>; <LINK REF="REF-Luotonen-1981" TYPE="REFERENCE">Luotonen 1981</LINK>). Recent studies have shown that nationwide implementation of PCVs may have changed the frequency of the causative otopathogens involved in AOM towards pneumococcal serotypes not included in the vaccines and non-typeable <I>H. influenzae</I> (ntHi) (<LINK REF="REF-Casey-2013" TYPE="REFERENCE">Casey 2013</LINK>; <LINK REF="REF-Coker-2010" TYPE="REFERENCE">Coker 2010</LINK>; <LINK REF="REF-Somech-2011" TYPE="REFERENCE">Somech 2011</LINK>; <LINK REF="REF-Wiertsema-2011" TYPE="REFERENCE">Wiertsema 2011</LINK>).<BR/>
</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>The marginal benefits of antibiotics for AOM in low-risk populations (<LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK>; <LINK REF="REF-Spiro-2008" TYPE="REFERENCE">Spiro 2008</LINK>; <LINK REF="REF-Venekamp-2013" TYPE="REFERENCE">Venekamp 2013</LINK>), the increasing problem of bacterial resistance against antibiotics (<LINK REF="REF-Arason-1996" TYPE="REFERENCE">Arason 1996</LINK>; <LINK REF="REF-Del-Castillo-1998" TYPE="REFERENCE">Del Castillo 1998</LINK>; <LINK REF="REF-Dagan-2000" TYPE="REFERENCE">Dagan 2000</LINK>; <LINK REF="REF-Goossens-2007" TYPE="REFERENCE">Goossens 2007</LINK>) and the high estimated direct and indirect annual costs associated with otitis media (OM) (<LINK REF="REF-Boonacker-2011" TYPE="REFERENCE">Boonacker 2011</LINK>; <LINK REF="REF-Kaplan-1997" TYPE="REFERENCE">Kaplan 1997</LINK>; <LINK REF="REF-Niemela-1999" TYPE="REFERENCE">Niemela 1999</LINK>) have prompted a search for effective vaccines to prevent AOM.</P>
</INTERVENTION>
<THEORY MODIFIED="2014-03-21 21:21:33 +1000" MODIFIED_BY="[Empty name]">
<P>With <I>S. pneumoniae </I>(pneumococcus) being the prime bacterial cause of AOM and childhood pneumonia, and one of the most common causes of invasive bacterial disease such as meningitis, research has focused on the prevention of pneumococcal infections with pneumococcal vaccines. Pneumococcal polysaccharide vaccines (PPVs) have been available for decades but have been shown to be poorly immunogenic in children below two years of age, who are most prone to pneumococcal infections. The first pneumococcal conjugate vaccines (PCVs), in which the pneumococcal capsular serotypes are covalently conjugated to carrier proteins, were developed in the 1990s and proved to be adequately immunogenic in infants and toddlers (<LINK REF="REF-Dagan-1997" TYPE="REFERENCE">Dagan 1997</LINK>; <LINK REF="REF-Eskola-1999" TYPE="REFERENCE">Eskola 1999</LINK>; <LINK REF="REF-Shinefield-1999" TYPE="REFERENCE">Shinefield 1999</LINK>). No further attention will be paid to the effect of PPVs, which were described in a prior version of this review (<LINK REF="REF-Straetemans-2003" TYPE="REFERENCE">Straetemans 2003</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>With AOM being amongst the most common diseases in early childhood, the need for a vaccine to prevent effectively AOM is high. Over the past decades various randomised controlled trials (RCTs) have been performed to assess the effects of pneumococcal vaccination to prevent AOM. From 2009 onwards, two multivalent PCVs (10- and 13-valent PCVs) have been licensed and are being implemented in nationwide immunisation programmes worldwide (<LINK REF="REF-WHO-2012" TYPE="REFERENCE">WHO 2012</LINK>). These new vaccines may have an increased benefit in preventing AOM (<LINK REF="REF-Marom-2014" TYPE="REFERENCE">Marom 2014</LINK>; <LINK REF="REF-O_x0027_Brien-2009" TYPE="REFERENCE">O'Brien 2009</LINK>). As such, it is important to provide an up-to-date systematic review on the effects of pneumococcal vaccination on preventing AOM. This review is an update of a Cochrane review first published in 2002 (<LINK REF="REF-Straetemans-2002" TYPE="REFERENCE">Straetemans 2002</LINK>), and updated in 2004 (<LINK REF="REF-Straetemans-2004" TYPE="REFERENCE">Straetemans 2004</LINK>) and 2009 (<LINK REF="REF-Jansen-2009" TYPE="REFERENCE">Jansen 2009</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-11-28 15:10:22 +1000" MODIFIED_BY="Liz Dooley">
<P>To assess the effect of pneumococcal conjugate vaccines (PCVs) in preventing AOM in children up to 12 years of age.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-03-21 21:25:59 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-02-08 01:33:55 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-11-28 15:11:24 +1000" MODIFIED_BY="Liz Dooley">
<P>RCTs of PCVs with prevention of AOM as an outcome in children aged 12 years or younger and a follow-up for at least six months.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Children up to 12 years of age.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-08-02 04:56:24 +1000" MODIFIED_BY="Liz Dooley">
<P>Multivalent PCVs.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-02-08 01:33:55 +1000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-11-28 15:12:18 +1000" MODIFIED_BY="[Empty name]">
<P>Frequency of all-cause AOM episodes defined as AOM irrespective of causative pathogen, as we considered this to be most relevant for children, parents and physicians.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-02-08 01:33:55 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Frequency of pneumococcal AOM.</LI>
<LI>Frequency of pneumococcal serotype-specific AOM.</LI>
<LI>Frequency of recurrent AOM (defined as three or more episodes in the last six months or four or more in the last year).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-03-21 01:19:20 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-03-21 01:19:20 +1000" MODIFIED_BY="[Empty name]">
<P>For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 11), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (1995 to November week 3, 2013); EMBASE (1995 to December 2013); CINAHL (2007 to December 2013); LILACS (2007 to December 2013) and Web of Science (2007 to December 2013).</P>
<P>We used the following search strategy to search CENTRAL and MEDLINE. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We adapted the search strategy to search EMBASE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), CINAHL (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>) and Web of Science (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">MEDLINE (Ovid)</HEADING>
<P>1 exp Otitis Media/<BR/>2 otitis media.tw.<BR/>3 aom.tw.<BR/>4 or/1-3<BR/>5 Pneumococcal Vaccines/<BR/>6 Vaccines, Conjugate/<BR/>7 Bacterial Vaccines/<BR/>8 (pneumococc* adj5 (vaccin* or conjugat* or immuni*)).tw,nm.<BR/>9 pcv*.tw,nm.<BR/>10 or/5-9<BR/>11 4 and 10</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>To increase the yield of relevant studies we reviewed the reference lists of all studies and review articles retrieved. We imposed no language restrictions on the searches. We checked ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>) and WHO ICTRP (<A HREF="http://www.who.int/trialsearch">http://www.who.int/trialsearch</A>) for completed and ongoing trials (3 December 2013).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-03-21 21:25:59 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-11-28 15:15:06 +1000" MODIFIED_BY="[Empty name]">
<P>Three review authors (ACF, RPV, CWB) independently screened titles and abstracts obtained from the database searches and reviewed the full text of the potentially relevant titles and abstracts against the inclusion criteria. We resolved disagreements by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-11-15 07:33:07 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (ACF, RPV) independently extracted data from the included studies. We resolved disagreements by discussion.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (ACF, RPV) independently assessed the methodological quality of the included trials. We resolved any disagreements by discussion. We assessed the methodological quality of included studies using the 'Risk of bias' tool as described in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We judged the following domains as high, low or unclear risk of bias: random sequence generation (selection bias), concealment of allocation (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias. We presented the results of the 'Risk of bias' assessment in a 'Risk of bias' graph (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and a 'Risk of bias' summary (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-11-28 15:22:50 +1000" MODIFIED_BY="[Empty name]">
<P>For both our primary and secondary outcomes we extracted the relative risks and their accompanying 95% CIs. Vaccine efficacy was estimated as 1 minus the relative risk (relative risk reduction (RRR)).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-12-03 03:56:36 +1000" MODIFIED_BY="[Empty name]">
<P>We included all types of RCTs. In case of cluster-randomised trials, we considered potential differences between the intervention effects being estimated.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-03-21 21:23:55 +1000" MODIFIED_BY="[Empty name]">
<P>We primarily presented data based on the intention-to-treat (ITT) principle, i.e. all data were analysed in the group to which the participants were originally allocated. As a secondary analysis, we presented data based on the per-protocol analysis. For each trial, we determined the number of missing data and whether the authors took duration of follow-up (and censoring) of individual participants into account in their statistical analyses.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-03-21 21:24:25 +1000" MODIFIED_BY="[Empty name]">
<P>Meta-analysis by pooling the results of the different trials is only useful and justified when trials show satisfactory clinical homogeneity in terms of study population, setting, intervention and outcome measures. We assessed clinical diversity between trials by reviewing the differences across trials. There was considerable clinical diversity between trials. First, there were differences in the timing of PCV administration, i.e. trials administering PCV during infancy and trials administering PCV later in life. As such, study populations varied from healthy infants to those at high risk of AOM. Second, the number of pneumococcal serotypes present in the vaccines, the type of conjugate method used and co-administration of non-bacterial vaccines differed across trials. For example, the protein D carrier, as used in one trial assessing the effect of PD-PCV11 (<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>), has been shown to be beneficial in reducing AOM caused by non-typeable<I> H. influenzae</I> (ntHi) (<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>), and as such may have an impact on all-cause AOM beyond pneumococcal AOM. Furthermore, co-administration of a trivalent flu vaccine with CRM197-PCV7, as used in another trial (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>), may have substantial impact on all-cause AOM. Finally, large differences in outcome assessments and AOM definitions were observed, varying from 'passive' (chart review at end of the trial) versus 'active' (parents were instructed to visit a physician in case of AOM symptoms) outcome assessments. As a consequence, AOM incidence in the control groups varied widely across the studies administering PCV during infancy, i.e. from 0.13 to 1.3 episodes per person-year. Therefore, we decided that a meta-analysis was not appropriate.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-03-21 21:24:57 +1000" MODIFIED_BY="[Empty name]">
<P>For each study, we searched the Internet and ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>) for available study protocols to determine whether all a priori defined outcomes have been reported in the publications.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-03-21 21:25:59 +1000" MODIFIED_BY="[Empty name]">
<P>As we refrained from pooling (see <LINK TAG="HETEROGENEITY_ASSESSMENT" TYPE="SECTION">Assessment of heterogeneity</LINK> section), we reported the effect estimates as presented by the individual trials. Where possible we reported the incidences of the various outcomes in the study arms together with the vaccine efficacy estimates, with 95% confidence intervals (CIs). However, due to limitations of the data, we reported alternative statistical measures in some instances.</P>
<P>We will briefly describe the methods we would have used if we had pooled the results. The generalised Cox proportional hazard method proposed by <LINK REF="REF-Andersen-1982" TYPE="REFERENCE">Andersen 1982</LINK> is regarded as the most appropriate to assess the effect of PCVs on AOM (<LINK REF="REF-Jahn_x002d_Eimermacher-2007" TYPE="REFERENCE">Jahn-Eimermacher 2007</LINK>). Under the assumption that the hazard rate is proportional between both groups over time and that the risk of AOM is not affected by previous episodes (although this assumption is not true), this model takes all available information into account; that is, all episodes (also the recurrent ones), differences in individual patient follow-up time and time until a case of AOM (<LINK REF="REF-Jahn_x002d_Eimermacher-2007" TYPE="REFERENCE">Jahn-Eimermacher 2007</LINK>). However, information on individual follow-up time until the first, second, third, etc. case of AOM is hard to obtain for each study to be included in the meta-analysis. Poisson regression is based on the assumption of a constant risk of AOM over time and that this risk is not affected by previous episodes of AOM. This method only requires the total follow-up time and total number of episodes and appears therefore a more feasible method for meta-analysis. Furthermore, Poisson regression seems not to be affected by the deviation from a constant risk over time, having very similar results for the effect of PCVs on AOM to the Anderson-Gill approach (<LINK REF="REF-Jahn_x002d_Eimermacher-2007" TYPE="REFERENCE">Jahn-Eimermacher 2007</LINK>). For Poisson regression, the treatment effect is measured as a rate ratio defined as follows: (total AOM episodes in pneumococcal vaccination group divided by the number of children in the pneumococcal vaccination group multiplied by the follow-up time in months) divided by (total AOM episodes in control group divided by the number of children in the control group multiplied by the follow-up time in months) (<LINK REF="REF-McCullagh-1989" TYPE="REFERENCE">McCullagh 1989</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-11-15 20:31:26 +1000" MODIFIED_BY="[Empty name]">
<P>Since the effect of PCVs on AOM may be influenced by the age at which the PCV was administered and the occurrence of previous AOM episodes, we described the studies accordingly, that is, those with vaccination in early infancy versus those with vaccination later in childhood.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>As mentioned, the clinical diversity between the studies was large and therefore we decided not to meta-analyse the trials nor conduct a sensitivity analysis on, for example: risk status (age, number of previous episodes), outcome measurement or adjustments for clustering in the case of a cluster-randomised trial.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-03-24 21:34:07 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-03-24 21:34:07 +1000" MODIFIED_BY="[Empty name]">
<P>See the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2014-03-21 21:28:15 +1000" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane review first published in 2002 (<LINK REF="REF-Straetemans-2002" TYPE="REFERENCE">Straetemans 2002</LINK>) and updated in 2004 (<LINK REF="REF-Straetemans-2004" TYPE="REFERENCE">Straetemans 2004</LINK>) and 2009 (<LINK REF="REF-Jansen-2009" TYPE="REFERENCE">Jansen 2009</LINK>). In the 2009 review, which included studies up to November 2007, eight publications were found eligible, concerning a total of seven RCTs (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). The studies of <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> and <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK> are part of the FinOM Vaccine Trial (three parallel-group trials using the same control group (hepatitis B vaccine) but two different treatment groups, each with a different type of 7-valent pneumococcal conjugate vaccine) and we therefore regarded them as two 'separate' trials in this review.<BR/>
</P>
<P>With the updated search (November 2007 to December 2013) we retrieved 171 records. Removing duplicates left 165 records. After screening titles and abstracts, we identified seven potentially eligible studies. After obtaining the full text of these papers, we excluded two studies as they studied the effect of pneumococcal vaccination on either otitis media with effusion (OME) (<LINK REF="STD-Le-2007" TYPE="STUDY">Le 2007</LINK>) or suppurative otitis media (<LINK REF="STD-Roy-2011" TYPE="STUDY">Roy 2011</LINK>). Furthermore, one RCT studying the effect of PCV on (recurrent) AOM was excluded as the children in the control group did not receive any type of vaccination (PCV versus no vaccination), while for outcome assessment non-blinded parents were instructed to visit the ear, nose and throat (ENT) department whenever they suspected an episode of AOM; the parental threshold to consult ENT departments may be lower in children allocated to the control treatment (no vaccination) than in those allocated to PCV, which may have introduced (detection) bias (<LINK REF="STD-Gisselsson-Solen-2011" TYPE="STUDY">Gisselsson Solen 2011</LINK>). Finally, one trial was excluded (<LINK REF="STD-Jokinen-2012" TYPE="STUDY">Jokinen 2012</LINK>), as this study was a re-analysis of the <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> study and did not include new outcome data useful to this review. This left three new publications eligible for inclusion (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>; <LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>). One study (<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>) was an additional analysis of the previously included <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> study. We did not identify any additional eligible trials after scanning the reference lists of the full-text papers and relevant systematic reviews. In searching ClinicalTrials.gov, we identified five ongoing RCTs (<LINK REF="STD-NCT00466947" TYPE="STUDY">NCT00466947</LINK>; <LINK REF="STD-NCT00861380" TYPE="STUDY">NCT00861380</LINK>; <LINK REF="STD-NCT01545375" TYPE="STUDY">NCT01545375</LINK>; <LINK REF="STD-NCT01735084" TYPE="STUDY">NCT01735084</LINK>; <LINK REF="STD-NCT01174849" TYPE="STUDY">NCT01174849</LINK>) (see also the <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> table).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-03-24 21:34:07 +1000" MODIFIED_BY="[Empty name]">
<P>The 11 included trials in this review originate from nine RCTs in total: (1) <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; (2) <LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>; (3) <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; (4) <LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; (5) <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; (6) <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>; (7) <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>; (8) <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; (9) <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Study designs</HEADING>
<P>Of these trials, eight were standard, individually randomised trials, while one trial was a cluster-randomised trial (<LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Study populations (early infancy versus later in life)</HEADING>
<P>Five trials (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>) included healthy infants and studied the effect of PCV administered in early infancy (first dose before the age of 12 months) on otitis media (OM), while the other four trials (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>; <LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>) assessed the effects of PCV administered at a later age on OM in either healthy infants (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>), or in children with a known history of respiratory disease, including OM (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions (type of PCV used)</HEADING>
<P>In all nine RCTs the control group received a control vaccine. In six trials the 7-valent PCV containing the polysaccharides of seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) coupled to the carrier protein CRM197 (a non-toxic mutant of diphtheria toxin) (CRM197-PCV7) was used as the intervention (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; <LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). In two of these studies a booster dose with 23-valent PPV (containing capsular polysaccharides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F) was given to all children (<LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>), while in one trial CRM197-PCV7 was administered with a trivalent inactivated influenza vaccine (TIV) (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>). The other three studies (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>) used different interventions, i.e. a 9-valent PCV containing the capsular polysaccharides of serotypes 1 and 5 besides those included in CRM197-PCV7, conjugated to CRM197 (CRM197-PCV9) (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>), a 7-valent PCV with the outer membrane complex of <I>N. meningitidis</I> serogroup B as protein carrier (OMPC-PCV7) (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>) and a subgroup of these children received a PPV23 as a booster dose and an 11-valent PCV containing the capsular polysaccharides of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, conjugated to protein D, which is a surface lipoprotein of <I>H. influenzae</I> (PD-PCV11) (<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Five studies applied a standardised diagnosis of AOM (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>), one study used standardised AOM registration forms to be completed by GPs (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>), whereas in two studies AOM episodes were extracted from a computerised data source containing all visits registered by physicians (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>). Another study assessed parent-reported AOM episodes (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>). Six studies additionally assessed the effect of PCVs on (serotype-specific) pneumococcal AOM (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). Three studies cultured middle ear fluid from all AOM episodes (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>), whereas one study only cultured it from the first AOM episode by myringotomy or from spontaneously draining ears (<LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). Two other studies assessed the effect on reported cultures that were taken in cases of spontaneously draining ears (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>). Three studies reported on the effects of PCVs on recurrent AOM (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>). Three of the included studies had all types of OM (including but not exclusively AOM) as an outcome (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>). Since the effect of PCVs on AOM may be influenced by the age at which the PCV was administered and the occurrence of previous episodes of AOM, we will further describe the studies accordingly; that is, those with vaccination in infancy versus those vaccinated later in childhood.
<BR/>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">PCV administered in early infancy (first dose before the age of 12 months)</HEADING>
<P>In the Northern California Kaiser Permanente (NCKP) trial (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>), the Finnish Otitis Media (FinOM) trial (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>) and the trial among Navajo and White Mountain Apache children (<LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>), the treatment group was administered CRM197-PCV7, at the age of two, four and six months and 12 to 15 months. In the NCKP trial (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>), infants were enrolled over a period of almost three years and had a follow-up time varying from about eight months to 30 months (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>) and 42 months (<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>), respectively. The trial was originally designed to investigate the effect of CRM197-PCV7 on invasive pneumococcal disease, with OM as a secondary outcome. Clinical diagnoses of OM were obtained from a computerised database collecting department-specific diagnosis checklists routinely marked by emergency physicians and paediatricians in the NCKP population. All clinical diagnoses of 'otitis media', 'otitis media, acute', 'middle ear effusion', 'otitis media, serous' or 'otitis media with effusion' were included.</P>
<P>The FinOM trial primarily aimed to assess the effect of CRM197-PCV7 on AOM (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>). Infants were followed until the age of 24 months and parents were encouraged to bring their child to the study clinic (established specifically for the purpose) for evaluation of symptoms suggesting respiratory infection or AOM. The diagnosis of AOM was standardised. In recent years, an additional analysis was performed as part of the <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> trial, including pneumolysin-PCR positive AOM (<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>).</P>
<P>The trial among Navajo and White Mountain Apache children was a cluster-randomised trial primarily aiming to assess the safety and efficacy of CRM197-PCV7 on invasive pneumococcal disease (<LINK REF="REF-O_x0027_Brien-2003" TYPE="REFERENCE">O'Brien 2003</LINK>). These children have some of the highest rates of invasive pneumococcal disease and otitis media in the world. Clinical and culture-proven OM were secondary outcomes measured in this trial and were assessed, at trial completion, by retrospective chart review. OM visits, as in every visit made by the study children through to two years of age and documented by their treating physician, were evaluated. An OM visit was defined as a visit for 'otitis media', 'acute otitis media', 'bilateral OM', 'chronic OM', 'OM with perforation', 'otorrhoea', 'pressure equalising tube placement', 'perforation tympanic membrane', 'serous OM' and 'bullous myringitis'. Further sub-categorisation was performed on AOM (either 'acute otitis media' or 'bilateral otitis media'), severe episodes, number of medical visits and pressure equalising tube placement.</P>
<P>
<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK> describes another part of the FinOM trial in which the index group was administered another 7-valent PCV, containing capsular polysaccharides of the same seven serotypes as used in the <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> study, i.e. OMPC-PCV7. Additionally, 22% of the children assigned to OMPC-PCV7 received PPV23 at the age of 12 months instead of a fourth OMPC-PCV7 dose. The follow-up and outcome measure was similar to <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>.</P>
<P>Finally, in <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK> (POET trial), an 11-valent PCV was administered at the ages of three, four, five months and 12 to 15 months, conjugated to protein D (PD-PCV11). Follow-up continued until the age of 24 to 27 months. The primary aim of the trial was to assess the effect on AOM and parents were advised to consult their paediatrician if their child was sick, had ear pain or had spontaneous ear discharge. The diagnosis of AOM was standardised.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">PCV administered at a later age (first dose administered after 12 months of age)</HEADING>
<P>
<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK> assessed the effect of CRM197-PCV9 on AOM in healthy day-care attendees aged 12 to 35 months. The vaccine was administered twice in 12- to 17-month-olds and once in 18- to 35-month-olds. The study was undertaken to examine the effect on respiratory infections. In 18 encounters during the two-year follow-up period that started one month after complete immunisation, parents were questioned about illness episodes, including OM episodes. The OM diagnosis was not physician-confirmed and not standardised.</P>
<P>
<LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK> and <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK> assessed the effect of pneumococcal vaccination on AOM in children aged one to seven years with a history of at least two AOM episodes in the year prior to study entry. CRM197-PCV7 was administered twice in one to two year-olds and once in two to seven year-olds followed by PPV23 six to seven months later. Children with underlying illnesses, including immuno-compromising conditions, were excluded. Both studies had a similar design and were conducted in parallel, but were analysed separately due to differences in study population (children included in <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK> had a more severe history of AOM and more frequent tympanostomy tube placement prior to study entry). Follow-up lasted about 24 months. Parents were instructed to visit the study clinics or their family physician, otolaryngologists or paediatrician for assessment in case of symptoms suggesting AOM. Physicians registered signs and symptoms of every AOM episode on standard registration forms. The diagnosis of AOM was standardised.</P>
<P>In <LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>, children aged between 18 and 72 months were randomly assigned in blocks of three in a 1:1:1 ratio to either (1) two doses of CRM197-PCV7 (six months apart) administered together with a trivalent inactivated influenza vaccine (TIV), (2) TIV plus placebo or (3) hepatitis B virus vaccine plus placebo. The main outcome measure was febrile respiratory tract infections including AOM during the influenza season. All children were eligible if they had a previous history of physician-diagnosed respiratory tract infections (RTI). This history included 'acute otitis media', 'cough', acute upper RTI', 'sinusitis', 'acute tonsillitis', 'acute laryngitis/tracheitis', 'acute bronchitis/bronchiolitis', 'influenza', 'pneumonia', 'pleurisy/pleural effusion' and 'other respiratory infections', all recorded according to the International Classification of Primary Care (ICPC). Each parent was instructed to keep a daily diary, recording signs or symptoms associated with RTI that began 14 days after the second dose and continued for six to 18 months (depending on year of inclusion). The parent was also instructed to measure the child's body temperature with a validated tympanic thermometer provided by the study centre. All GP visits were recorded as well and the GP was instructed to complete a form including diagnosis and treatment.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-03-21 21:34:27 +1000" MODIFIED_BY="[Empty name]">
<P>Four studies were excluded for various reasons (<LINK REF="STD-Gisselsson-Solen-2011" TYPE="STUDY">Gisselsson Solen 2011</LINK>; <LINK REF="STD-Jokinen-2012" TYPE="STUDY">Jokinen 2012</LINK>; <LINK REF="STD-Le-2007" TYPE="STUDY">Le 2007</LINK>; <LINK REF="STD-Roy-2011" TYPE="STUDY">Roy 2011</LINK>) (see also <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-03-21 21:36:05 +1000" MODIFIED_BY="[Empty name]">
<P>We judged the methodological quality of the included studies to be moderate to high. For further details on the risk of bias in included studies see the 'Risk of bias' graph (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and 'Risk of bias' summary (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Concealment of allocation was adequately described in six of the nine included trials, while in the other three trials it was unclear due to insufficient information (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). We judged random sequence generation to be adequate in five of the nine trials, while in four trials insufficient information was provided on the method of random sequence generation used (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>; <LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Authors of all studies indicated that the studies were double-blinded, but for two of the nine trials insufficient information was provided on how blinding was performed (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-03-21 21:35:20 +1000" MODIFIED_BY="[Empty name]">
<P>Overall, we judged the risk of bias due to incomplete outcome data to be low. In the <LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK> study (extension of <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>), we judged the risk of attrition bias to be high, as 27% in the PCV group and 26% in the control group did not stay in the Kaiser Permanente healthcare database to the end of follow-up (April 1999), while missing data were either substantial or unclear in two trials (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>), and in one trial the distribution across treatment groups of those who were not included in the primary efficacy analysis was unclear (<LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>).</P>
<P>Almost all trials did take duration of follow-up of individuals into account by using either the generalised Cox proportional hazard method (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>), or Poisson regression analyses (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>). One trial used a Chi<SUP>2</SUP> test to compare rates of AOM, which is considered suboptimal (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>In three trials, we judged the risk of reporting bias to be low as prespecified (primary and secondary) outcomes were listed in ClinicalTrials.gov (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>). <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK> used a subset of the 4476 children that were included in the cluster-randomised trial to estimate the efficacy of PCV on the main outcome of the trial, i.e. invasive pneumococcal disease for a retrospective chart review on OM. Of the 4476 children that were included in the main study (<LINK REF="REF-O_x0027_Brien-2003" TYPE="REFERENCE">O'Brien 2003</LINK>), 944 were randomly selected and 856 met the chart review criteria (<LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>). In four trials no study protocol was identified (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>), while in two trials the study protocol was uploaded at ClinicalTrials.gov but after the completion of the study (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-03-21 21:36:05 +1000" MODIFIED_BY="[Empty name]">
<P>In four trials we detected no other potential sources of bias (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). In three trials study enrolment was stopped as a result of interim analyses (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>). These interim analyses were prespecified and performed by independent data safety monitoring boards; we therefore judged the risk of bias as low. In one trial a sample of the children (22%) assigned to OMPC-PCV7 received PPV23 at the age of 12 months instead of a fourth OMPC-PCV7 dose. However, it was unclear how it was known that only those particular children should receive that intervention. Moreover, in one trial PCV was administered together with a influenza vaccine (CRM197-PCV7/TIV) (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>). As such, it is not possible to determine the effect of PCV only in this study.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-03-21 21:39:58 +1000" MODIFIED_BY="[Empty name]">
<P>The main results are described in<B> </B>
<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>In total, we included nine trials with 48,426 children, ranging from 74 to 37,868 participants per study. Five trials included infants who received primary vaccinations before six months of age (47,108 participants in total) (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>); one study included day-care attendees aged 12 to 35 months (264 participants) (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>), two trials included one to seven year-olds with a history of acute otitis media (AOM) (457 participants) (<LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>), and one trial included children aged 18 to 72 months with a previously diagnosed respiratory tract infection (RTI) (597 participants) (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>).</P>
<P>We present the results of the individual trials as reported in the published papers since meta-analysis was inappropriate due to substantial differences between studies. Therefore, the statistical methods by which the data were analysed in each study are briefly assessed. <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>, <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>, <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>, <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK> and <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK> all used the generalised Cox proportional hazard method proposed by <LINK REF="REF-Andersen-1982" TYPE="REFERENCE">Andersen 1982</LINK>, currently regarded as the most optimal for analysing this kind of data (see <LINK TAG="DATA_SYNTHESIS" TYPE="SECTION">Data synthesis</LINK>). <LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK> compared rates of AOM, but rather than comparing them by Poisson regression (which would presumably yield results similar to those obtained with the Anderson approach), the Chi<SUP>2</SUP> test was used, which is suboptimal for comparing rates. <LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK> used Poisson regression to compare rates of AOM, accounting for the potential dependency of observations between individuals. <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK> was a cluster-randomised trial. The incidence rate ratio was calculated with a Poisson regression with sandwich variance estimation to account for within-community correlation.</P>
<P>Effect estimates of pneumococcal conjugate vaccines (PCVs) on all AOM episodes, pneumococcal AOM and recurrent AOM are summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> and <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>, respectively.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Frequency of all-cause AOM episodes (defined as AOM irrespective of causative pathogen)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Effect of PCV administered in early infancy</HEADING>
<P>CRM197-PCV7 reduced overall AOM episodes by -5% in high-risk children to 6% in low-risk children in intention-to-treat (ITT) analyses and by 0% in high-risk children to 7% in low-risk children in per-protocol analyses (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>), whereas OMPC-PCV7 appeared to have no effect on overall AOM episodes (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>). In a per-protocol analysis, PD-PCV11 led to a 34% (95% confidence interval (CI) 21% to 44%) relative reduction in AOM episodes (<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>). However, the AOM incidence rate in the control group was low compared to the other studies and the absolute risk difference was small (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Effect of PCV administered at a later age</HEADING>
<P>In per-protocol analyses, CRM197-PCV9 administered in healthy 12- to 35-month-olds reduced overall otitis media (OM) episodes by 17% (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>), while CRM197-PCV7 followed by PPV23 in one to seven-year-olds with a history of AOM did not reduce the occurrence of further AOM episodes (<LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). CRM197-PCV7 administered together with a trivalent influenza vaccine (CRM197-PCV7/TIV) reduced overall AOM episodes by 57% (95% CI 6% to 80%) in per-protocol analysis (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>), as compared to hepatitis B (HBV)/placebo vaccination. However, the vaccine efficacy of trivalent influenza vaccine (TIV)/placebo, as compared to HBV/placebo, on overall AOM, appeared to be even larger, i.e. 71% (95% CI 30% to 88%).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Frequency of pneumococcal AOM</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Effect of PCV administered in early infancy</HEADING>
<P>The efficacy of PCVs for pneumococcal AOM varied from 25% for OMPC-PCV7 (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>), 20% to 34% for CRM197-PCV7 (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>), to 52% for PD-PCV11 (<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>). CRM197-PCV7 and PD-PCV11 also seemed to reduce AOM caused by the so-called cross-reactive serotypes which are non-vaccine serotypes with a serogroup that is included in the vaccine (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>), while OMPC-PCV7 failed to show cross-protection (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>). Although not statistically significant, CRM197-PCV7 and OMPC-PCV7 were associated with an increase in non-vaccine-type AOM (replacement) (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>) and <I>H. influenzae</I> AOM, while PD-PCV11 did not show pneumococcal replacement and showed a vaccine efficacy of 35% against AOM caused by <I>H. influenzae</I> (<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Effect of PCV administered at a later age</HEADING>
<P>Only one study reported the effect of CRM197-PCV7 followed by PPV23 on pneumococcal AOM (<LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). In per-protocol analysis, pneumococcal AOM was reduced by 34%, while non-vaccine-type AOM was reduced by 21%, although none of the estimates was statistically significant (because of small numbers).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Frequency of pneumococcal serotype-specific AOM</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Effect of PCV administered in early infancy</HEADING>
<P>The effect of CRM197-PCV7 on vaccine-type pneumococcal AOM varied from 54% to 65% in ITT analyses (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>), and from 57% to 67% in per-protocol analyses (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>). In per-protocol analyses, OMPC-PCV7 appeared to reduce vaccine-type AOM by 56% (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>), while PD-PCV11 led to a 58% relative reduction in vaccine-type AOM (<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Effect of PCV administered at a later age</HEADING>
<P>In per-protocol analysis, CRM197-PCV7 followed by PPV23 reduced pneumococcal serotype-specific AOM by a statistically non-significant 52% (<LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). None of the other trials reported on pneumococcal (serotype-specific) AOM.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Frequency of recurrent AOM (defined as three or more episodes in the last six months or four or more in the last year)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Effect of PCV administered in early infancy</HEADING>
<P>CRM197-PCV7 seemed to reduce recurrent AOM by 9% to 10% in ITT analyses (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>), whereas the administration of PD-PCV11 was associated with a statistically non-significant decrease of 56% in recurrent AOM in per-protocol analysis (<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Effect of PCV administered at a later age</HEADING>
<P>None of the four trials in older children reported the effect of PCV on recurrent AOM.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-03-24 21:45:02 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-03-24 21:45:02 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical diversity between the nine included randomised controlled trials (RCTs), in terms of study population, number of pneumococcal serotypes present in the vaccines, type of conjugate method used, co-administration of non-bacterial vaccines and outcome measures, was considerable and we therefore did not pool results. The main findings are summarised in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>Based on current evidence of the effects of pneumococcal conjugate vaccines (PCVs) for preventing acute otitis media (AOM), the licensed 7-valent PCV has modest beneficial effects in healthy infants; in the studies in healthy infants, the licensed CRM197-PCV7 was associated with a relative risk reduction (RRR) of overall AOM of -5% (in high-risk children) to 7% (in low-risk children) and OMPC-PCV7 did not reduce overall AOM episodes. PD-PCV11 showed a large reduction in all-cause AOM episodes, i.e. 34%, compared to the PCV7 studies. In healthy toddlers, CRM197-PCV9 was associated with a non-significant RRR of 17% of parent-reported OM episodes. Administering PCV7 in older children with a history of AOM appears to have no beneficial effect on preventing further AOM episodes.</P>
<P>In infants, PCV led to a substantial reduction in AOM caused by <I>S. pneumoniae</I> (RRR ranging from 20% to 52%). This beneficial effect seems to be mainly driven by the large effect of PCV on vaccine-type pneumococcal AOM (RRR ranging from 54% to 67%). In contrast, no or even a negative contribution of PCV was observed for non-vaccine-type pneumococcal AOM (RRR ranging from -33% to 9%). For PCV7, there was a tendency toward replacement disease by non-vaccine pneumococci as well as by other otopathogens, such as <I>H. influenzae</I>. OMPC-PCV7 appeared to increase the proportion of AOM caused by <I>M. catarrhalis</I> (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>). This means that while PCVs are effective against vaccine-serotype pneumococcal AOM, there is high potential for replacement by other pathogens. Although we are confident in the effect estimate for PCV7 administered in infancy on all-cause AOM and pneumococcal AOM, uncertainty exists about the effect of conjugate vaccines that include more than seven pneumococcal serotypes and the impact of replacement by non-vaccine-type pneumococci or other otopathogens (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>The large effect of PD-PCV11 on all-cause AOM found in the trial of <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK> may not be solely explained by the four additional serotypes covered by PD-PCV11 compared to PCV7. Part of the effect might be related to the protein D, which has the potential to provide protection against <I>H. influenzae</I> strains causing AOM (<LINK REF="REF-Forsgren-2008" TYPE="REFERENCE">Forsgren 2008</LINK>), or may be secondary to the prevention of pneumococcal AOM in the first place with ntHi as a pathogen more frequently observed in previously inflamed middle ears (<LINK REF="REF-Dagan-2013" TYPE="REFERENCE">Dagan 2013</LINK>; <LINK REF="REF-Kaur-2013" TYPE="REFERENCE">Kaur 2013</LINK>). Furthermore, <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK> used a stringent outcome definition for AOM (children diagnosed with AOM by the paediatrician were subsequently referred to the otorhinolaryngologist for confirmation of diagnosis), which may have contributed to the low AOM incidence rate observed in <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>; this is about 10 times lower than the incidence reported by other studies in infancy. It might be that in <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK> more severe episodes of AOM were identified and consequently the effect may only apply to these more severe episodes. The case definition potentially also introduced a different selection of pathogens as early findings suggest that <I>S. pneumoniae </I>was associated with more severe episodes (<LINK REF="REF-Howie-1970" TYPE="REFERENCE">Howie 1970</LINK>). However, a subsequent post hoc analysis of <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>, using a case definition of AOM very close to the <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK> definition, showed only a slight impact on the vaccine efficacy estimates compared to the original case definitions (<LINK REF="REF-Palmu-2008" TYPE="REFERENCE">Palmu 2008</LINK>).</P>
<P>The effect of a multivalent PCV, i.e. CRM197-PCV9, on AOM was evaluated in healthy toddlers attending day-care (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>). As such, the effect of PCV9 in early life remains uncertain. In toddlers, PCV9 led to a non-statistically significant RRR of all-cause AOM of 17%. However, this result should be interpreted with caution as the outcome measure (parent-reported AOM) and the statistics were suboptimal.</P>
<P>In AOM there is a high potential for replacement by other pathogens that are common colonisers of the nasopharynx. CRM197-PCV7 is known to affect nasopharyngeal carriage of pneumococci, with a shift from vaccine-type pneumococci to non-vaccine-type pneumococci and other bacteria that may have pathogenic potential (<LINK REF="REF-Block-2006" TYPE="REFERENCE">Block 2006</LINK>; <LINK REF="REF-Casey-2013" TYPE="REFERENCE">Casey 2013</LINK>; <LINK REF="REF-Coker-2010" TYPE="REFERENCE">Coker 2010</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="REF-Obaro-1996" TYPE="REFERENCE">Obaro 1996</LINK>; <LINK REF="REF-Somech-2011" TYPE="REFERENCE">Somech 2011</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>; <LINK REF="REF-Wiertsema-2011" TYPE="REFERENCE">Wiertsema 2011</LINK>). Nasopharyngeal carriage results from a recent RCT with a commercially available 10-valent protein D pneumococcal conjugate vaccine (PD-PCV10) show similar bacterial colonisation patterns of vaccine-type and non-vaccine-type pneumococci (<I>H. influenzae</I>,<I> M. catarrhalis</I> and <I>Staphylococcus aureus </I>(<I>S. aureus</I>)) to CRM197-PCV7 in healthy Dutch children up to two years of age (<LINK REF="REF-Van-den-Bergh-2013" TYPE="REFERENCE">Van den Bergh 2013</LINK>). The middle ear is directly connected to the nasopharynx and by lowering the carriage of vaccine-type pneumococci, a niche is created for other bacteria with a pathogenic potential (<LINK REF="REF-Block-2006" TYPE="REFERENCE">Block 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>; <LINK REF="REF-Veenhoven-2004" TYPE="REFERENCE">Veenhoven 2004</LINK>). Future studies may provide more precise information about the extent and impact of such replacement in AOM when administering conjugate vaccines that include more than seven pneumococcal serotypes.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-03-21 21:48:56 +1000" MODIFIED_BY="[Empty name]">
<P>The nine RCTs included in this review on the effect of PCV on AOM in children show large heterogeneity regarding study design (standard, individually randomised trials versus group randomised trial), population (age of administration of PCV and baseline risk of AOM), intervention (vaccine valency (7-/9-/11-valent vaccines), carrier protein (CRM197, OMPC or PD), presence or absence of additional booster immunisation with PCV or PPV23, co-administration of non-bacterial vaccines and outcome assessment and definition (active surveillance for standardised physician-diagnosed AOM, passive collection of diagnoses of AOM or parent-reported AOM). Furthermore, in the infant studies on AOM focusing on bacteriology (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>), the control groups varied markedly in the proportions of <I>S. pneumoniae</I>, <I>H. influenzae</I> and <I>M. catarrhalis</I> in middle ear fluid, possibly related to time and geographic region as well as case definition, which will affect the result of all-cause AOM episodes prevented by pneumococcal vaccines. Additionally, three studies included older otitis-prone children, so the intervention was aimed at secondary or even tertiary prevention and not primary prevention (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). The reduced efficacy of CRM197-PCV7 in children already with a history of AOM may be explained by an increased susceptibility to subsequent infections, not only with non-vaccine-type pneumococci but also other nasopharyngeal colonisers, due to 'damage' already suffered by the middle ear mucosa caused by prior AOM (<LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). Another explanation, although debated, could be the non-protective, impaired antibody responses of children who are otitis-prone (<LINK REF="REF-Pichichero-2013" TYPE="REFERENCE">Pichichero 2013</LINK>; <LINK REF="REF-Wiertsema-2012" TYPE="REFERENCE">Wiertsema 2012</LINK>). Thus, it appears that the age at which PCV is administered, a history of AOM episodes, or both, modifies the effect of PCV on AOM, despite the fact that age alone could not be identified as a statistically significant effect modifier (<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>We judged the methodological quality of the included studies to be moderate to high. Although we were not able to pool the results of the separate trials due to substantial clinical diversity, the overall results were consistent.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>In this review, we strictly adhered to the prespecified review protocol. Three review authors independently searched all relevant electronic databases by using a search syntax comprising all relevant synonyms for PCV and AOM. Additionally, we performed a broad Internet search to identify potentially relevant articles. To increase the yield of relevant studies, we reviewed the reference lists of all identified studies and systematic reviews or meta-analyses.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-03-21 21:49:35 +1000" MODIFIED_BY="[Empty name]">
<P>Our main findings are in agreement with two other systematic reviews on the effect of PCV in children, indicating that PCV may provide some protection against otitis media, but that other factors could also have contributed to the observed effect estimates (<LINK REF="REF-Pavia-2009" TYPE="REFERENCE">Pavia 2009</LINK>; <LINK REF="REF-Taylor-2012" TYPE="REFERENCE">Taylor 2012</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-03-24 21:47:31 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-03-24 21:47:24 +1000" MODIFIED_BY="[Empty name]">
<P>The prevention of invasive pneumococcal disease has been the primary reason for many Western countries to introduce pneumococcal conjugate vaccine (PCV) into their national infant immunisation protocol. The beneficial effect on overall acute otitis media (AOM) episodes with CRM197-PCV7 appears to be modest in healthy, low-risk infants and therefore promoting PCV solely to reduce AOM for the individual does not seem justified. For countries that have not yet implemented PCV in the immunisation protocol and for countries that do not implement a catch-up vaccination programme for older children up to five years of age, the question is whether it would be beneficial to administer the vaccine to older children with a history of AOM. In two trials in older children with a history of AOM, no beneficial effect of CRM197-PCV7 on further episodes of AOM was observed (<LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>; <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>), while in a third trial CRM197-PCV7 administered together with a trivalent influenza vaccine (CRM197-PCV7/TIV) reduced overall AOM episodes by 57% during the influenza season, compared to hepatitis B vaccination (HBV)/placebo vaccination (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>). However, the vaccine efficacy of trivalent influenza vaccine (TIV)/placebo, compared to HBV/placebo, on overall AOM appeared to be even larger (i.e. 71%), indicating that CRM197-PCV7 after infancy may even have negative effects on AOM. As such, there is at present no reason to administer the vaccine to older children with a history of previous AOM episodes in order to protect them against further AOM episodes. In fact, early vaccination before the first AOM episode might be required for prevention of middle ear mucosal damage.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-03-24 21:47:31 +1000" MODIFIED_BY="[Empty name]">
<P>Uncertainty exists nowadays about 1) the effect of widespread implementation of pneumococcal conjugate vaccination on AOM in everyday practice, 2) the effect of conjugate vaccines that include more than seven pneumococcal serotypes and 3) the impact of replacement by non-vaccine-type pneumococci or other otopathogens. Although the beneficial effect of CRM197-PCV7 on all-cause AOM in randomised controlled trials (RCTs) seems modest, real-world experience gained with widespread CRM197-PCV7 vaccination in infants after 2000 in the United States suggests that the impact on AOM may be much greater than that seen in the clinical studies (<LINK REF="REF-Taylor-2012" TYPE="REFERENCE">Taylor 2012</LINK>). Post-licensure studies, comparing rates of ambulatory visits related to AOM in the immediate years before and after widespread implementation of routine CRM197-PCV7 vaccination in children younger than 12 years of age, have reported a substantial decrease (mean decrease in ambulatory visits of 19%). Quickly after the introduction of PCV in the United States decreases in AOM visits and antibiotic prescriptions were reported in children below two years of age (43% and 42%, respectively (<LINK REF="REF-Zhou-2008" TYPE="REFERENCE">Zhou 2008</LINK>)), a decline in the frequency of otitis media of 17% and 28% in birth cohorts from Tennessee and upstate New York (<LINK REF="REF-Poehling-2007" TYPE="REFERENCE">Poehling 2007</LINK>) and an overall downward trend in otitis media-related health care use in children aged below six years over the years 2001 to 2011 (<LINK REF="REF-Marom-2014" TYPE="REFERENCE">Marom 2014</LINK>). A recent non-US observational study showed a decline of AOM in Norwegian children aged 12 to 18 months and 18 to 36 months of 14% and 8%, respectively (<LINK REF="REF-Magnus-2012" TYPE="REFERENCE">Magnus 2012</LINK>). These larger benefits found in observational studies, compared to the effects reported in RCTs, might be due to indirect herd effects and may have important implications for the cost-effectiveness analyses for PCV. However, the findings of the observational studies must be interpreted with caution as variability in baseline incidence, study population, case definition and implementation of AOM treatment guidelines could have influenced the AOM incidences reported. For example, results from Boston in the US showed that the decline in uncomplicated AOM, treatment failure and AOM relapse was at least as large in the 2000 to 2004 period compared to 1996 to 2000 (<LINK REF="REF-Sox-2008" TYPE="REFERENCE">Sox 2008</LINK>). Therefore the 'true' contribution of PCV to reducing AOM incidence remains uncertain (<LINK REF="REF-Sox-2008" TYPE="REFERENCE">Sox 2008</LINK>).</P>
<P>Whether the decline in AOM will continue or wane with time is relevant and deserves ongoing monitoring. A waning effect in AOM incidence after implementation of PCV may be explained by replacement by other otopathogens such as <I>H. influenzae</I> or an increase in the proportion of AOM caused by non-CRM197-PCV7 pneumococcal serotypes, including serotypes 3, 6A and 19A (<LINK REF="REF-Alonso-2013" TYPE="REFERENCE">Alonso 2013</LINK>; <LINK REF="REF-Block-2004" TYPE="REFERENCE">Block 2004</LINK>; <LINK REF="REF-Casey-2013" TYPE="REFERENCE">Casey 2013</LINK>; <LINK REF="REF-Coker-2010" TYPE="REFERENCE">Coker 2010</LINK>; <LINK REF="REF-Couloigner-2012" TYPE="REFERENCE">Couloigner 2012</LINK>; <LINK REF="REF-McEllistrem-2005" TYPE="REFERENCE">McEllistrem 2005</LINK>; <LINK REF="REF-Pichichero-2007" TYPE="REFERENCE">Pichichero 2007</LINK>). As previously mentioned, two infant studies found an increase in non-vaccine-type pneumococcal AOM after administration of CRM197-PCV7, albeit not statistically significant, as well as an increase in <I>H. influenzae</I> (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>). An increase in <I>H. influenzae</I> was also observed in the post-marketing studies on AOM in the US (<LINK REF="REF-Block-2004" TYPE="REFERENCE">Block 2004</LINK>; <LINK REF="REF-Casey-2004" TYPE="REFERENCE">Casey 2004</LINK>). In addition, the study in older children with previous AOM episodes demonstrated an increase in AOM caused by <I>S. aureus</I> (<LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>). In view of the effects of PCVs on nasopharyngeal carriage of pathogens, awareness of the possibility of infections caused by replacement pathogens is warranted. Besides a reduction of nasopharyngeal vaccine-type serotypes, which is presumed to induce herd effects, replacing pneumococcal serotypes may not only lead to replacement disease in vaccines but also in the population. Continuing surveillance of pneumococcal disease in different settings and geographic locations is therefore of utmost importance. Currently, several RCTs with different (newly licensed, multivalent) PCVs administered during early infancy are ongoing to establish their effects on AOM (<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>). The results of these studies may provide a better understanding of the role of PCVs in preventing all-cause AOM (<LINK REF="REF-Hausdorff-2013" TYPE="REFERENCE">Hausdorff 2013</LINK>), including mixed <I>S. pneumoniae</I> and<I> H. influenzae</I> infections (<LINK REF="REF-Dagan-2013" TYPE="REFERENCE">Dagan 2013</LINK>), bacterial-bacterial interactions (<LINK REF="REF-Van-den-Bergh-2012" TYPE="REFERENCE">Van den Bergh 2012</LINK>) and long-term effects of shifts in pneumococcal serotypes (<LINK REF="REF-Spijkerman-2012" TYPE="REFERENCE">Spijkerman 2012</LINK>).</P>
<P>We emphasise the need for uniform outcome measures (case definitions of AOM) and uniform presentation of results to allow for meta-analysis by pooling the results in future. Reporting of the total number of AOM episodes in the different study arms, together with the total follow-up time in person-months, is preferred. These figures should also be available on the basis of intention-to-treat analysis and not only on the basis of per-protocol analysis.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-12-06 20:53:47 +1000" MODIFIED_BY="Liz Dooley">
<P>The authors are indebted to Reinier Veenhoven (in memoriam) for the invaluable collaboration and his contributions to prior versions of the review.</P>
<P>We would like to thank Angelique Jansen, Masja Straetemans and Gerhard Zielhuis for their contributions to prior versions of this review. We would also like to thank the following people for commenting on previous updates of this review: Barbara Loe Fisher, Morio Aihara,<B> </B>Mark Jones and Paul Glasziou.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-03-20 23:17:05 +1000" MODIFIED_BY="[Empty name]">
<P>During the initial phase of the review ACF was employed by the Medical Affairs department of GlaxoSmithKline B.V., the Netherlands. Currently ACF is an employee of the Bacterial Vaccines Discovery and Early Development group at Crucell. Neither company was involved in any aspect of the submitted work.</P>
<P>AS: My team at UCL is supported by an NIHR Research Professorship award to establish an infrastructure and programme of clinical trials in ENT, Hearing and Balance. My institution has received a grant from GSK for a study on the microbiology of acute tympanostomy tube otorrhoea.</P>
<P>EH: I have authored a paper on the design of the CAPITA study (Neth J Med), but have not been involved in the actual conduct of that study, nor does it pose a conflict of interest to the current work.</P>
<P>ES: For research on pneumococcal vaccines, carriage and surveillance studies, I received money paid by the institution, by governmental agencies and by pharmaceutical companies GSK and Pfizer and paid to the institution or collaborating institutions. Furthermore, I participate in Independent Data Monitoring Committees and Advisory Boards for pharmaceutical companies for vaccine studies and/or respiratory tract infections with fees paid to the institution. In general, all fees are always paid to the institution and used for research purposes.</P>
<P>RPV, CWB and RD declare no conflicts of interest in the current work.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-03-21 21:57:34 +1000" MODIFIED_BY="[Empty name]">
<P>ACF, RPV co-ordinated the review.<BR/>ACF, RPV, CWB were involved in data collection.<BR/>ACF and RPV performed 'Risk of bias' assessment and analysis of data.<BR/>All review authors (ACF, ES,EH, RPV, CWB, AS, RD) were involved in designing and writing the review and interpreting the data.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-11-15 07:33:09 +1000" MODIFIED_BY="[Empty name]">
<P>None.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2014-03-21 21:58:37 +1000" MODIFIED_BY="[Empty name]">
<P>The focus in research has shifted from the use of pneumococcal polysaccharide vaccines (PPVs) to pneumococcal conjugate vaccines (PCVs) in children and the role of PPVs in the prevention of AOM in children has merely been assessed following PCVs and no longer as a primary intervention. Therefore, the focus of the current review has shifted from the effect of PPVs to the effect of PCVs on acute otitis media. No further attention will be paid to the effect of PPVs, which were described in prior versions of this review (<LINK REF="REF-Straetemans-2003" TYPE="REFERENCE">Straetemans 2003</LINK>).</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-03-21 22:03:55 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-03-21 01:19:30 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-12-01 19:40:12 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2000" MODIFIED="2013-12-01 19:37:18 +1000" MODIFIED_BY="[Empty name]" NAME="Black 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-08-03 01:26:49 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al</AU>
<TI>Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>3</NO>
<PG>187-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dagan-2001" MODIFIED="2013-07-20 01:02:13 +1000" MODIFIED_BY="[Empty name]" NAME="Dagan 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-07-20 01:02:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D</AU>
<TI>Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>10</NO>
<PG>951-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eskola-2001" MODIFIED="2013-12-01 19:40:12 +1000" MODIFIED_BY="[Empty name]" NAME="Eskola 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-01 19:40:12 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;UI - 0&lt;/p&gt;" NOTES_MODIFIED="2013-12-01 19:40:12 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al</AU>
<TI>Efficacy of a pneumococcal conjugate vaccine against acute otitis media</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>6</NO>
<PG>403-9</PG>
<IDENTIFIERS MODIFIED="2008-04-29 19:52:42 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fireman-2003" MODIFIED="2013-12-01 19:39:53 +1000" MODIFIED_BY="[Empty name]" NAME="Fireman 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-12-01 19:39:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P</AU>
<TI>Impact of the pneumococcal conjugate vaccine on otitis media</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>10-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jansen-2008" MODIFIED="2013-11-15 21:23:21 +1000" MODIFIED_BY="[Empty name]" NAME="Jansen 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-15 21:23:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E</AU>
<TI>Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Pediatrics</SO>
<YR>2008</YR>
<VL>153</VL>
<PG>764-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kilpi-2003" MODIFIED="2013-07-20 00:58:00 +1000" MODIFIED_BY="[Empty name]" NAME="Kilpi 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-07-20 00:58:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, et al</AU>
<TI>Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>9</NO>
<PG>1155-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Brien-2008" MODIFIED="2013-11-15 21:23:15 +1000" MODIFIED_BY="[Empty name]" NAME="O'Brien 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-15 21:23:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien KL, David AB, Chandran A, Moulton LH, Reid R, Weatherholtz R, et al</AU>
<TI>Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2008</YR>
<VL>27</VL>
<PG>71-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palmu-2009" MODIFIED="2013-11-15 21:23:10 +1000" MODIFIED_BY="[Empty name]" NAME="Palmu 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-11-15 21:23:10 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palmu AA, Saukkoriipi A, Jokinen J, Leinonen M, Kilpi TM</AU>
<TI>Efficacy of pneumococcal conjugate vaccine against PCR-positive acute otitis media</TI>
<SO>Vaccine</SO>
<YR>2009</YR>
<VL>27</VL>
<PG>1490-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prymula-2006" MODIFIED="2008-06-18 10:55:18 +1000" MODIFIED_BY="[Empty name]" NAME="Prymula 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-06-18 10:55:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al</AU>
<TI>Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomised double-blind efficacy study</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<NO>9512</NO>
<PG>740-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Kempen-2006" MODIFIED="2008-06-16 22:45:12 +1000" MODIFIED_BY="[Empty name]" NAME="Van Kempen 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-06-16 22:45:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Kempen MJ, Vermeiren JS, Vaneechoutte M, Claeys G, Veenhoven RH, Rijkers GT, et al</AU>
<TI>Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2006</YR>
<VL>70</VL>
<NO>2</NO>
<PG>275-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veenhoven-2003" MODIFIED="2008-06-18 10:55:35 +1000" MODIFIED_BY="[Empty name]" NAME="Veenhoven 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-06-18 10:55:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, Bruin J, et al</AU>
<TI>Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9376</NO>
<PG>2189-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-03-21 00:52:58 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Gisselsson-Solen-2011" MODIFIED="2013-11-15 21:23:03 +1000" MODIFIED_BY="[Empty name]" NAME="Gisselsson Solen 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-15 21:23:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gisselsson-Soln M, Melhus A, Hermansson A</AU>
<TI>Pneumococcal vaccination in children at risk of developing recurrent acute otitis media - a randomized study</TI>
<SO>Acta Paediatrica</SO>
<YR>2011</YR>
<VL>100</VL>
<PG>1354-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jokinen-2012" MODIFIED="2013-11-15 21:22:58 +1000" MODIFIED_BY="[Empty name]" NAME="Jokinen 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-15 21:22:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jokinen J, Palmu AA, Kilpi T</AU>
<TI>Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2012</YR>
<VL>55</VL>
<PG>1673-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-2007" MODIFIED="2013-11-15 21:22:51 +1000" MODIFIED_BY="[Empty name]" NAME="Le 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-11-15 21:22:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le TM, Rovers MM, Veenhoven RH, Sanders EA, Schilder AG</AU>
<TI>Effect of pneumococcal vaccination on otitis media with effusion in children older than 1 year</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2007</YR>
<VL>166</VL>
<PG>1049-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Roy-2011" MODIFIED="2014-03-21 00:52:58 +1000" MODIFIED_BY="[Empty name]" NAME="Roy 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-03-21 00:52:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Roy E, Steinhoff MC, Omer SB, Arifeen SE, Raqib R, Breiman R, et al</AU>
<TI>Clinical effectiveness of pneumococcal conjugate vaccine in suppurative otitis media: a randomized controlled trial in Bangladeshi Infants</TI>
<SO>Pediatric Academic Societies Annual Meeting (April 28 - May 1)</SO>
<YR>2011</YR>
<CY>Boston, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-26 19:37:53 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-26 19:37:53 +1000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/920/CN-00831920/frame.html"/>
</IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-07-20 01:05:18 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2014-03-21 01:19:30 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00466947" MODIFIED="2014-03-21 01:19:30 +1000" MODIFIED_BY="[Empty name]" NAME="NCT00466947" YEAR="">
<REFERENCE MODIFIED="2014-03-21 01:19:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00466947</AU>
<TI>COMPAS: Phase III, Double-blind, Randomized Study to Demonstrate Efficacy of GSK Biologicals' Pneumococcal Conjugate Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media (AOM)</TI>
<SO>clinicaltrials.gov/show/NCT00466947</SO>
<YR>(accessed 1 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00861380" MODIFIED="2013-12-03 05:46:16 +1000" MODIFIED_BY="[Empty name]" NAME="NCT00861380" YEAR="">
<REFERENCE MODIFIED="2013-12-03 05:46:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00861380</AU>
<TI>Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (FinIP)</TI>
<SO>clinicaltrials.gov/show/NCT00861380</SO>
<YR>(accessed 1 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-26 16:11:23 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01174849" MODIFIED="2013-12-06 21:25:12 +1000" MODIFIED_BY="[Empty name]" NAME="NCT01174849" YEAR="">
<REFERENCE MODIFIED="2013-12-06 21:25:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01174849</AU>
<TI>Pneumococcal Vaccines Early and in Combination (PREVIX_COMBO)</TI>
<SO>clinicaltrials.gov/show/NCT01174849</SO>
<YR>(accessed 1 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01545375" MODIFIED="2013-12-03 05:46:31 +1000" MODIFIED_BY="[Empty name]" NAME="NCT01545375" YEAR="5375">
<REFERENCE MODIFIED="2013-12-03 05:46:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01545375</AU>
<TI>Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children</TI>
<SO>clinicaltrials.gov/show/NCT01545375</SO>
<YR>(accessed 1 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01735084" MODIFIED="2013-12-03 05:46:36 +1000" MODIFIED_BY="[Empty name]" NAME="NCT01735084" YEAR="5084">
<REFERENCE MODIFIED="2013-12-03 05:46:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01735084</AU>
<TI>Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life (PREV-IX_B)</TI>
<SO>clinicaltrials.gov/show/NCT01735084</SO>
<YR>(accessed 1 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-03-21 22:03:55 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-03-21 01:06:27 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alonso-2013" MODIFIED="2013-11-25 11:00:44 +1000" MODIFIED_BY="[Empty name]" NAME="Alonso 2013" TYPE="JOURNAL_ARTICLE">
<AU>Alonso M, Marimon JM, Ercibengoa M, Prez-Yarza EG, Prez-Trallero E</AU>
<TI>Dynamics of Streptococcus pneumoniae serotypes causing acute otitis media isolated from children with spontaneous middle-ear drainage over a 12-year period (1999-2010) in a region of northern Spain</TI>
<SO>PLoS ONE</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>1</NO>
<PG>e54333</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andersen-1982" MODIFIED="2011-11-17 08:14:23 +1000" MODIFIED_BY="[Empty name]" NAME="Andersen 1982" TYPE="JOURNAL_ARTICLE">
<AU>Andersen PK, Gill RD</AU>
<TI>Cox regression model for counting processes: a large sample study</TI>
<SO>Annals of Statistics</SO>
<YR>1982</YR>
<VL>10</VL>
<NO>4</NO>
<PG>1100-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arason-1996" MODIFIED="2013-11-25 11:01:08 +1000" MODIFIED_BY="Liz Dooley" NAME="Arason 1996" TYPE="JOURNAL_ARTICLE">
<AU>Arason VA, Kristinsson KG, Sigurdsson JA, Stefnsdttir G, Mlstad S, Gudmundsson S</AU>
<TI>Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7054</NO>
<PG>387-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Block-2004" MODIFIED="2011-11-17 08:14:34 +1000" MODIFIED_BY="[Empty name]" NAME="Block 2004" TYPE="JOURNAL_ARTICLE">
<AU>Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, et al</AU>
<TI>Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>9</NO>
<PG>829-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Block-2006" MODIFIED="2008-04-29 20:31:43 +1000" MODIFIED_BY="[Empty name]" NAME="Block 2006" TYPE="JOURNAL_ARTICLE">
<AU>Block SL</AU>
<TI>Searching for the Holy Grail of acute otitis media</TI>
<SO>Archives of Diseases in Childhood</SO>
<YR>2006</YR>
<VL>91</VL>
<NO>12</NO>
<PG>959-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bluestone-1992" MODIFIED="2008-06-16 22:38:55 +1000" MODIFIED_BY="[Empty name]" NAME="Bluestone 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bluestone CD, Stephenson JS, Martin LM</AU>
<TI>Ten-year review of otitis media pathogens</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1992</YR>
<VL>11</VL>
<NO>8 Suppl</NO>
<PG>7-11</PG>
<IDENTIFIERS MODIFIED="2008-04-29 20:32:09 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Boonacker-2011" MODIFIED="2013-11-25 11:01:39 +1000" MODIFIED_BY="[Empty name]" NAME="Boonacker 2011" TYPE="JOURNAL_ARTICLE">
<AU>Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM</AU>
<TI>Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review</TI>
<SO>Pharmacoeconomics</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>3</NO>
<PG>199-211</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casey-2004" MODIFIED="2008-10-14 06:59:13 +1000" MODIFIED_BY="[Empty name]" NAME="Casey 2004" TYPE="JOURNAL_ARTICLE">
<AU>Casey JR, Pichichero ME</AU>
<TI>Changes in the frequency and pathogens causing acute otitis media in 1995-2003</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2004</YR>
<VL>9</VL>
<PG>824-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casey-2013" MODIFIED="2013-11-25 11:02:00 +1000" MODIFIED_BY="[Empty name]" NAME="Casey 2013" TYPE="JOURNAL_ARTICLE">
<AU>Casey JR, Kaur R, Friedel VC, Pichichero ME</AU>
<TI>Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2013</YR>
<VL>32</VL>
<PG>805-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coker-2010" MODIFIED="2013-11-25 11:02:16 +1000" MODIFIED_BY="[Empty name]" NAME="Coker 2010" TYPE="JOURNAL_ARTICLE">
<AU>Coker TR, Chan LS, Newberry SJ, Limbos MA, Suttorp MJ, Shekelle PG, et al</AU>
<TI>Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>304</VL>
<PG>2161-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Couloigner-2012" MODIFIED="2013-11-25 11:02:25 +1000" MODIFIED_BY="[Empty name]" NAME="Couloigner 2012" TYPE="JOURNAL_ARTICLE">
<AU>Couloigner V, Levy C, Franois M, Bidet P, Cohen R, et al</AU>
<TI>Pathogens implicated in acute otitis media failures after 7-valent pneumococcal conjugate vaccine implementation in France: distribution, serotypes, and resistance levels</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>2</NO>
<PG>154-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dagan-1997" MODIFIED="2008-04-29 20:36:03 +1000" MODIFIED_BY="[Empty name]" NAME="Dagan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dagan R, Melamed R, Zamir O, Leroy O</AU>
<TI>Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>11</NO>
<PG>1053-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dagan-2000" MODIFIED="2013-11-25 11:02:48 +1000" MODIFIED_BY="[Empty name]" NAME="Dagan 2000" TYPE="JOURNAL_ARTICLE">
<AU>Dagan R</AU>
<TI>Treatment of acute otitis media - challenges in the era of antibiotic resistance</TI>
<SO>Vaccine</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>Suppl 1</NO>
<PG>9-16</PG>
<IDENTIFIERS MODIFIED="2008-04-29 20:36:44 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Dagan-2013" MODIFIED="2014-03-21 00:55:28 +1000" MODIFIED_BY="[Empty name]" NAME="Dagan 2013" TYPE="JOURNAL_ARTICLE">
<AU>Dagan R, Leibovitz E, Greenberg D, Bakaletz L, Givon-Lavi N</AU>
<TI>Mixed pneumococcal-nontypeable Haemophilus influenzae otitis media is a distinct clinical entity with unique epidemiologic characteristics and pneumococcal serotype distribution</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2013</YR>
<VL>208</VL>
<NO>7</NO>
<PG>1152-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Del-Castillo-1998" MODIFIED="2008-04-29 20:37:15 +1000" MODIFIED_BY="[Empty name]" NAME="Del Castillo 1998" TYPE="JOURNAL_ARTICLE">
<AU>del Castillo F, Baquero-Artigao F, Garcia-Perea A</AU>
<TI>Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>2</NO>
<PG>94-7</PG>
<IDENTIFIERS MODIFIED="2008-04-29 20:37:15 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Eskola-1999" MODIFIED="2008-04-29 20:37:44 +1000" MODIFIED_BY="[Empty name]" NAME="Eskola 1999" TYPE="JOURNAL_ARTICLE">
<AU>Eskola J, Anttila M</AU>
<TI>Pneumococcal conjugate vaccines</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>6</NO>
<PG>543-51</PG>
<IDENTIFIERS MODIFIED="2008-04-29 20:37:44 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Forsgren-2008" MODIFIED="2008-04-29 20:39:43 +1000" MODIFIED_BY="[Empty name]" NAME="Forsgren 2008" TYPE="JOURNAL_ARTICLE">
<AU>Forsgren A, Riesbeck K, Janson H</AU>
<TI>Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2008</YR>
<VL>46</VL>
<NO>5</NO>
<PG>726-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goossens-2007" MODIFIED="2008-06-16 22:39:36 +1000" MODIFIED_BY="[Empty name]" NAME="Goossens 2007" TYPE="JOURNAL_ARTICLE">
<AU>Goossens H, Ferech M, Coenen S, Stephens P</AU>
<TI>Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>44</VL>
<NO>8</NO>
<PG>1091-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hausdorff-2013" MODIFIED="2014-03-21 00:56:31 +1000" MODIFIED_BY="[Empty name]" NAME="Hausdorff 2013" TYPE="JOURNAL_ARTICLE">
<AU>Hausdorff W, Mrkvan T, Moreira M, Ruiz Guinazu J, Borys D</AU>
<TI>Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on pneumococcal disease. Proceedings of the 28th International Congress of Chemotherapy and Infection Incorporating the 14th Asia-Pacific Congress of Clinical Microbiology and Infection; 2013 June 5-8; Yokohama, Japan</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2013</YR>
<VL>42 Suppl 2</VL>
<PG>S157</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heikkinen-1999" MODIFIED="2011-11-17 08:15:06 +1000" MODIFIED_BY="[Empty name]" NAME="Heikkinen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Heikkinen T, Thint M, Chonmaitree T</AU>
<TI>Prevalence of various respiratory viruses in the middle ear during acute otitis media</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>4</NO>
<PG>260-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-03-21 00:58:26 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Intervention 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howie-1970" MODIFIED="2014-02-08 00:11:48 +1000" MODIFIED_BY="[Empty name]" NAME="Howie 1970" TYPE="JOURNAL_ARTICLE">
<AU>Howie VM, Ploussard JH, Lester RL Jr</AU>
<TI>Otitis media: a clinical and bacteriological correlation</TI>
<SO>Pediatrics</SO>
<YR>1970</YR>
<VL>45</VL>
<NO>1</NO>
<PG>29-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobs-1998" MODIFIED="2009-02-03 09:19:31 +1000" MODIFIED_BY="Liz Dooley" NAME="Jacobs 1998" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs MR, Dagan R, Appelbaum PC, Burch DJ</AU>
<TI>Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1998</YR>
<VL>42</VL>
<NO>3</NO>
<PG>589-95</PG>
<IDENTIFIERS MODIFIED="2008-04-29 20:46:55 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Jahn_x002d_Eimermacher-2007" MODIFIED="2008-04-29 20:49:01 +1000" MODIFIED_BY="[Empty name]" NAME="Jahn-Eimermacher 2007" TYPE="JOURNAL_ARTICLE">
<AU>Jahn-Eimermacher A, du Prel JB, Schmitt HJ</AU>
<TI>Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: a methodological overview of statistical practice in randomized controlled clinical trials</TI>
<SO>Vaccine</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>33</NO>
<PG>6237-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1997" MODIFIED="2009-02-02 19:29:18 +1000" MODIFIED_BY="[Empty name]" NAME="Kaplan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan B, Wandstrat TL, Cunningham JR</AU>
<TI>Overall cost in the treatment of otitis media</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>2 Suppl</NO>
<PG>9-11</PG>
<IDENTIFIERS MODIFIED="2008-04-29 20:49:31 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kaur-2013" MODIFIED="2013-11-15 22:21:41 +1000" MODIFIED_BY="[Empty name]" NAME="Kaur 2013" TYPE="JOURNAL_ARTICLE">
<AU>Kaur R, Casey JR, Pichichero ME</AU>
<TI>Relationship with original pathogen in recurrence of acute otitis media after completion of amoxicillin/clavulanate: bacterial relapse or new pathogen</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>11</NO>
<PG>1159-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kvaerner-1997" MODIFIED="2014-03-21 00:59:27 +1000" MODIFIED_BY="[Empty name]" NAME="Kvaerner 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kvaerner KJ, Nafstad P, Hagen JA, Mair IW, Jaakkola JJ</AU>
<TI>Recurrent acute otitis media: the significance of age at onset</TI>
<SO>Acta Oto-Laryngologica</SO>
<YR>1997</YR>
<VL>117</VL>
<NO>4</NO>
<PG>578-84</PG>
<IDENTIFIERS MODIFIED="2008-04-29 20:49:57 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2013-11-25 11:05:00 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luotonen-1981" MODIFIED="2014-03-21 00:59:52 +1000" MODIFIED_BY="[Empty name]" NAME="Luotonen 1981" TYPE="JOURNAL_ARTICLE">
<AU>Luotonen J, Herva E, Karma P, Timonen M, Leinonen M, Makela PH</AU>
<TI>The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1981</YR>
<VL>13</VL>
<NO>3</NO>
<PG>177-83</PG>
<IDENTIFIERS MODIFIED="2008-04-29 20:50:42 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Magnus-2012" MODIFIED="2013-11-25 11:05:19 +1000" MODIFIED_BY="[Empty name]" NAME="Magnus 2012" TYPE="JOURNAL_ARTICLE">
<AU>Magnus MC, Vestrheim DF, Nystad W, Hberg SE, Stigum H</AU>
<TI>Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>9</NO>
<PG>951-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marom-2014" MODIFIED="2014-03-21 01:00:31 +1000" MODIFIED_BY="[Empty name]" NAME="Marom 2014" TYPE="JOURNAL_ARTICLE">
<AU>Marom T, Tan A, Wilkinson GS, Pierson KS, Freeman JL, Chonmaitree T</AU>
<TI>Trends in otitis media-related health care use in the United States, 2001-2011</TI>
<SO>JAMA Pediatrics</SO>
<YR>2014</YR>
<VL>168</VL>
<NO>1</NO>
<PG>68-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCullagh-1989" MODIFIED="2014-03-21 01:00:47 +1000" MODIFIED_BY="[Empty name]" NAME="McCullagh 1989" TYPE="BOOK">
<AU>McCullagh P, Nelder JA</AU>
<SO>Generalized Linear Models</SO>
<YR>1989</YR>
<PB>Chapman and Hall</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McEllistrem-2005" MODIFIED="2014-03-21 01:01:03 +1000" MODIFIED_BY="[Empty name]" NAME="McEllistrem 2005" TYPE="JOURNAL_ARTICLE">
<AU>McEllistrem MC, Adams JM, Patel K, Medelsohn AB, Kaplan SL, Bradley JS, et al</AU>
<TI>Acute otitis media due to penicillin-non-susceptible <I>Streptococcus pneumoniae</I> before and after the introduction of the pneumococcal conjugate vaccine</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>1738-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moulton-2001" MODIFIED="2013-11-15 21:19:37 +1000" MODIFIED_BY="[Empty name]" NAME="Moulton 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moulton LH, O'Brien KL, Kohberger R, Chang I, Reid R, Weatherholtz R, et al</AU>
<TI>Design of a group-randomized Streptococcus pneumoniae vaccine trial</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2001</YR>
<VL>22</VL>
<PG>438-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Niemela-1999" MODIFIED="2008-04-29 20:51:20 +1000" MODIFIED_BY="[Empty name]" NAME="Niemela 1999" TYPE="JOURNAL_ARTICLE">
<AU>Niemela M, Uhari M, Mottonen M, Pokka T</AU>
<TI>Costs arising from otitis media</TI>
<SO>Acta Paediatrica</SO>
<YR>1999</YR>
<VL>88</VL>
<NO>5</NO>
<PG>553-6</PG>
<IDENTIFIERS MODIFIED="2008-04-29 20:51:20 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2003" MODIFIED="2013-12-03 04:48:35 +1000" MODIFIED_BY="[Empty name]" NAME="O'Brien 2003" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al</AU>
<TI>Efficacy and safety of a seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9381</NO>
<PG>255-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2009" MODIFIED="2013-11-15 21:19:30 +1000" MODIFIED_BY="[Empty name]" NAME="O'Brien 2009" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M</AU>
<TI>New vaccines against otitis media: projected benefits and cost-effectiveness</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>123</VL>
<PG>1452-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Obaro-1996" MODIFIED="2008-06-18 10:56:40 +1000" MODIFIED_BY="[Empty name]" NAME="Obaro 1996" TYPE="JOURNAL_ARTICLE">
<AU>Obaro SK, Adegbola RA, Banya WA, Greenwood BM</AU>
<TI>Carriage of pneumococci after pneumococcal vaccination</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9022</NO>
<PG>271-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmu-2008" MODIFIED="2014-02-08 00:16:41 +1000" MODIFIED_BY="[Empty name]" NAME="Palmu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Palmu A, Jokinen J, Kilpi T; Finnish Otitis Media Study Group</AU>
<TI>Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine</TI>
<SO>Vaccine</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>20</NO>
<PG>2466-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmu-2013a" MODIFIED="2013-12-09 10:46:28 +1000" MODIFIED_BY="[Empty name]" NAME="Palmu 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, et al</AU>
<TI>Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial</TI>
<SO>Lancet</SO>
<YR>2013</YR>
<VL>381</VL>
<NO>9862</NO>
<PG>214-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmu-2013b" MODIFIED="2014-03-21 01:03:12 +1000" MODIFIED_BY="[Empty name]" NAME="Palmu 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, et al</AU>
<TI>Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>3</NO>
<PG>205-12</PG>
<IDENTIFIERS MODIFIED="2014-03-21 01:03:12 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-21 01:03:12 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S1473-3099(13)70338-4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pavia-2009" MODIFIED="2013-11-25 11:06:10 +1000" MODIFIED_BY="[Empty name]" NAME="Pavia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF</AU>
<TI>Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>123</VL>
<NO>6</NO>
<PG>e1103-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pichichero-2007" MODIFIED="2014-03-21 01:03:40 +1000" MODIFIED_BY="[Empty name]" NAME="Pichichero 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Casey JR</AU>
<TI>Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>298</VL>
<PG>1772-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pichichero-2013" MODIFIED="2013-11-15 22:22:28 +1000" MODIFIED_BY="[Empty name]" NAME="Pichichero 2013" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Casey JR, Almudevar A</AU>
<TI>Nonprotective responses to pediatric vaccines occur in children who are otitis prone</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>11</NO>
<PG>1163-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poehling-2007" MODIFIED="2014-03-21 01:04:06 +1000" MODIFIED_BY="[Empty name]" NAME="Poehling 2007" TYPE="JOURNAL_ARTICLE">
<AU>Poehling KA, Szilagyi PG, Grijalva CG, Martin SW, LaFleur B, Mitchel E, et al</AU>
<TI>Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>4</NO>
<PG>707-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rovers-2006" MODIFIED="2008-06-18 10:56:47 +1000" MODIFIED_BY="[Empty name]" NAME="Rovers 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, et al</AU>
<TI>Antibiotics for acute otitis media: a meta-analysis with individual patient data</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<NO>9545</NO>
<PG>1429-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shinefield-1999" MODIFIED="2008-06-16 22:41:35 +1000" MODIFIED_BY="[Empty name]" NAME="Shinefield 1999" TYPE="JOURNAL_ARTICLE">
<AU>Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, et al</AU>
<TI>Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>9</NO>
<PG>757-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Somech-2011" MODIFIED="2013-11-15 21:19:18 +1000" MODIFIED_BY="[Empty name]" NAME="Somech 2011" TYPE="JOURNAL_ARTICLE">
<AU>Somech I, Dagan R, Givon-Lavi N, Porat N, Raiz S, Leiberman A, et al</AU>
<TI>Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine</TI>
<SO>Vaccine</SO>
<YR>2011</YR>
<VL>29</VL>
<PG>4202-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sox-2008" MODIFIED="2008-10-14 07:07:33 +1000" MODIFIED_BY="[Empty name]" NAME="Sox 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sox CM, Finkelstein JA, Yin R, Kleinman K, Lieu TA</AU>
<TI>Trends in otitis media treatment failure and relapse</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>121</VL>
<PG>674-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spijkerman-2012" MODIFIED="2014-03-21 01:05:02 +1000" MODIFIED_BY="[Empty name]" NAME="Spijkerman 2012" TYPE="JOURNAL_ARTICLE">
<AU>Spijkerman J, Prevaes SM, van Gils EJ, Veenhoven RH, Bruin JP, Bogaert D, et al</AU>
<TI>Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of <I>S. pneumoniae</I>,<I> S. aureus</I>,<I> H. influenzae</I> and <I>M. catarrhalis</I>
</TI>
<SO>PloS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>6</NO>
<PG>e39730</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spiro-2008" MODIFIED="2008-04-29 21:01:35 +1000" MODIFIED_BY="[Empty name]" NAME="Spiro 2008" TYPE="JOURNAL_ARTICLE">
<AU>Spiro DM, Arnold DH</AU>
<TI>The concept and practice of a wait-and-see approach to acute otitis media</TI>
<SO>Current Opinion in Pediatrics</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>1</NO>
<PG>72-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2012" MODIFIED="2013-11-25 11:07:14 +1000" MODIFIED_BY="[Empty name]" NAME="Taylor 2012" TYPE="JOURNAL_ARTICLE">
<AU>Taylor S, Marchisio P, Vergison A, Harriague J, Hausdorff WP, Haggard M</AU>
<TI>Impact of pneumococcal conjugate vaccination on otitis media: a systematic review</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2012</YR>
<VL>54</VL>
<NO>12</NO>
<PG>1765-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teele-1989" NAME="Teele 1989" TYPE="JOURNAL_ARTICLE">
<AU>Teele DW, Klein JO, Rosner B</AU>
<TI>Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study</TI>
<SO>Journal Infectious Disease</SO>
<YR>1989</YR>
<VL>160</VL>
<PG>83-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Bergh-2012" MODIFIED="2014-03-21 01:05:42 +1000" MODIFIED_BY="[Empty name]" NAME="Van den Bergh 2012" TYPE="JOURNAL_ARTICLE">
<AU>van den Bergh MR, Biesbroek G, Rossen JW, de Steenhuijsen Piters WA, Bosch AA, van Gils EJ, et al</AU>
<TI>Associations between pathogens in the upper respiratory tract of young children: interplay between viruses and bacteria</TI>
<SO>PloS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>10</NO>
<PG>e47711</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Bergh-2013" MODIFIED="2013-12-01 19:38:22 +1000" MODIFIED_BY="[Empty name]" NAME="Van den Bergh 2013" TYPE="JOURNAL_ARTICLE">
<AU>van den Bergh MR, Spijkerman J, Swinnen KM, Franois NA, Pascal TG, Borys D, et al</AU>
<TI>Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2013</YR>
<VL>56</VL>
<NO>3</NO>
<PG>e30-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Veenhoven-2004" MODIFIED="2008-05-28 22:43:41 +1000" MODIFIED_BY="[Empty name]" NAME="Veenhoven 2004" TYPE="JOURNAL_ARTICLE">
<AU>Veenhoven RH, Bogaert D, Schilder AG, Rijkers GT, Uiterwaal CS, Kiezebrink HH, et al</AU>
<TI>Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>7</NO>
<PG>911-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Venekamp-2013" MODIFIED="2013-11-27 14:32:57 +1000" MODIFIED_BY="[Empty name]" NAME="Venekamp 2013" TYPE="COCHRANE_REVIEW">
<AU>Venekamp RP, Sanders S, Glasziou PP, Del Mar CB, Rovers MM</AU>
<TI>Antibiotics for acute otitis media in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-11-27 14:32:57 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2013-11-27 14:32:57 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD000219.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2012" MODIFIED="2013-12-09 10:47:15 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 2012" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Pneumococcal vaccines WHO position paper &#8211; 2012 &#8211; Recommendations</TI>
<SO>Vaccine</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>32</NO>
<PG>4717-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiertsema-2011" MODIFIED="2013-11-15 22:08:09 +1000" MODIFIED_BY="[Empty name]" NAME="Wiertsema 2011" TYPE="JOURNAL_ARTICLE">
<AU>Wiertsema SP, Kirkham LA, Corscadden KJ, Mowe EN, Bowman JM, Jacoby P, et al</AU>
<TI>Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule</TI>
<SO>Vaccine</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>32</NO>
<PG>5163-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiertsema-2012" MODIFIED="2014-03-21 01:06:27 +1000" MODIFIED_BY="[Empty name]" NAME="Wiertsema 2012" TYPE="JOURNAL_ARTICLE">
<AU>Wiertsema SP, Corscadden KJ, Mowe EN, Zhang G, Vijayasekaran S, Coates HL, et al</AU>
<TI>IgG responses to pneumococcal and Haemophilus influenzae protein antigens are not impaired in children with a history of recurrent acute otitis media</TI>
<SO>PLoS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>11</NO>
<PG>e49061</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhou-2008" MODIFIED="2013-11-15 22:23:18 +1000" MODIFIED_BY="Liz Dooley" NAME="Zhou 2008" TYPE="JOURNAL_ARTICLE">
<AU>Zhou F, Shefer A, Kong Y, Nuorti JP</AU>
<TI>Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>121</VL>
<PG>253-60</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-03-21 22:03:55 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Jansen-2009" MODIFIED="2013-11-16 00:01:53 +1000" MODIFIED_BY="[Empty name]" NAME="Jansen 2009" TYPE="COCHRANE_REVIEW">
<AU>Jansen AG, Hak E, Veenhoven RH, Damoiseaux RA, Schilder AG, Sanders EA</AU>
<TI>Pneumococcal conjugate vaccines for preventing otitis media</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-11-16 00:01:45 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-16 00:01:45 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001480.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Straetemans-2002" MODIFIED="2013-11-16 00:01:26 +1000" MODIFIED_BY="[Empty name]" NAME="Straetemans 2002" TYPE="COCHRANE_REVIEW">
<AU>Straetemans M, Sanders EA, Veenhoven RH, Schilder AG, Damoiseaux RA, Zielhuis GA</AU>
<TI>Pneumococcal vaccines for preventing otitis media</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2. Art, No.: CD001480</NO>
<IDENTIFIERS MODIFIED="2013-11-16 00:01:26 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-16 00:01:26 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001480"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Straetemans-2003" MODIFIED="2008-05-28 23:12:43 +1000" MODIFIED_BY="[Empty name]" NAME="Straetemans 2003" TYPE="JOURNAL_ARTICLE">
<AU>Straetemans M, Sanders EAM, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA</AU>
<TI>Review of randomized controlled trials on pneumococcal vaccination for prevention of otitis media</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>6</NO>
<PG>515-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Straetemans-2004" MODIFIED="2014-03-21 22:03:55 +1000" MODIFIED_BY="[Empty name]" NAME="Straetemans 2004" TYPE="COCHRANE_REVIEW">
<AU>Straetemans M, Sanders EAM, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA</AU>
<TI>Pneumococcal vaccines for preventing otitis media</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2013-11-16 00:00:42 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-16 00:00:42 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001480.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-03-24 21:50:12 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-03-24 21:50:12 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-2000">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, at individual level</P>
<P>
<B>Design -</B> standard parallel-group design</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Follow-up - </B>6 to 31 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-15 07:38:05 +1000" MODIFIED_BY="Liz Dooley">
<P>
<B>N -</B> 37,868 healthy infants<BR/>
<B>Age -</B> 2 months</P>
<P>
<B>Setting -</B> 23 medical centres within Northern California Kaiser Permanente (NCKP), USA</P>
<P>
<B>Inclusion criteria -</B> healthy children aged 2 months</P>
<P>
<B>Exclusion criteria -</B> children with sickle cell disease, known immunodeficiency, any serious chronic or progressive disease, a history of seizures or a history of either pneumococcal or meningococcal disease</P>
<P>
<B>Baseline characteristics -</B> not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-20 23:22:16 +1000" MODIFIED_BY="[Empty name]">
<P>Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine (PCV7) or a meningococcus type C conjugate vaccine (MenC) at 2, 4, 6 and 12 to 15 months of age</P>
<P>
<B>Tx -</B> PCV7 (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to carrier protein CRM197); N = 18,927 received 1 dose or more of the vaccine (unclear how many children were included in otitis media analyses)<BR/>
<B>C -</B> MenC (10 G of group C oligosaccharide conjugated to carrier protein CRM197); N = 18,941 received 1 dose or more of the vaccine (unclear how many children were included in otitis media analyses)<BR/>
<B>Additional vaccines - </B>routine childhood vaccines were administered at the recommended ages: diphtheria-tetanus toxoid-whole cell pertussis vaccine (DTwP) or diphtheria-tetanus toxoid-acellular pertussis vaccine (DTaP); oral poliovirus vaccine or inactivated poliovirus vaccine; <I>Haemophilus influenzae</I> type B; hepatitis B; measles-mumps-rubella vaccine; varicella. Initially all participants received a vaccine combining Haemophilus b conjugate and DTwP into the opposite leg and oral poliovirus vaccine concurrently. When recommendations changed the protocol was amended to allow administration of DTaP and inactivated poliovirus vaccine. Vaccines not given concomitantly were given at least 2 weeks apart from study vaccine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>protective efficacy of PCV7 against invasive pneumococcal disease caused by vaccine serotypes</P>
<P>
<B>Secondary outcomes -</B> effect of PCV7 on (a) number of otitis media episodes in fully vaccinated per-protocol; (b) number of otitis media visits; (c) time to frequent otitis media (defined as 3 or more episodes in 6 months or 4 or more in 12 months); (d) number of tympanostomy tubes placements; (e) number of cases of spontaneous draining ruptured tympanic membranes with culture of a vaccine serotype pneumococcus</P>
<P>Clinical diagnoses of acute otitis media were obtained from computerised data sources using diagnoses registered by emergency physicians and paediatricians in the NCKP population. Each clinic visit constituted a new episode unless it was classified as a follow-up visit. A visit &lt; 21 days after another otitis media visit was always considered a follow-up visit. A visit 42 days or more after the most recent otitis media visit was considered a new episode. Visits occurring between 21 and 42 days, if the appointment was made &lt; 3 days in advance, were considered new episodes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-21 22:43:42 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dagan-2001">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, at individual level</P>
<P>
<B>Design -</B> standard parallel-group design</P>
<P>
<B>Intention-to-treat (ITT) -</B> no, per- protocol analysis</P>
<P>
<B>Follow-up - </B>2 years starting 1 month after complete immunisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 264 healthy infants (261 children were included in clinical follow-up)<BR/>
<B>Age - </B>12 to 35 months</P>
<P>
<B>Setting -</B> 8 day-care centres in Beer-Sheva, Israel</P>
<P>
<B>Inclusion criteria -</B> healthy children aged 12 to 35 months</P>
<P>
<B>Exclusion criteria -</B> children that received any vaccine within a 4-week period before, or were scheduled to receive any vaccine during the 4 weeks after the administration of the study vaccines, or received immunoglobulin within 8 weeks of study vaccination, known or suspected impairment of immunologic functions, major congenital malformation or serious chronic disease, known hypersensitivity to any components of the study vaccine, previous severe vaccine-associated adverse reaction, previous vaccination with any pneumococcal or meningococcal vaccine, febrile illness (rectal temperature, 38 C) within 72 h before vaccination</P>
<P>
<B>Baseline characteristics -</B> described and balanced (Table 1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-28 15:34:06 +1000" MODIFIED_BY="Liz Dooley">
<P>Children were randomly allocated to either a 9-valent pneumococcal conjugate vaccine (PCV9) or a meningococcus type C conjugate vaccine (MenC). Children aged 12 to 17 months at time of enrolment received 2 intramuscular injections 2 to 3 months apart and those 18 to 35 months at time of enrolment received 1 intramuscular injection</P>
<P>
<B>Tx -</B> PCV9 (containing the polysaccharides of serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F conjugated to carrier protein CRM197); N = 131<BR/>
<B>C -</B> MenC (10 G of group C oligosaccharide conjugated to carrier protein CRM197); N = 130<BR/>
<B>Additional vaccines - </B>not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>effect of PCV9 on nasopharyngeal carriage of <I>S. pneumoniae</I> of the serotypes found in the vaccines in general and antibiotic-resistant <I>S. pneumoniae</I> in particular<BR/>
</P>
<P>
<B>Secondary outcomes -</B> effect of PCV9 on parent-reported respiratory infections including otitis media</P>
<P>18 encounters were planned for each child during the 2-year follow-up period. During the first year encounters were planned to take place monthly and during the second year bimonthly. At each visit the parents were questioned about illness and antibiotic use since the last visit. Illness episodes were divided into 4 categories:<BR/>(1) upper respiratory infections; (2) lower respiratory problems; (3) otitis media; and (4) other illnesses. Only episodes starting 1 month after complete immunisation were counted</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Participants lost to follow-up during first 12 months - total:</B> 32/261 (12.3%)</P>
<P>
<B>Participants lost to follow-up during first 12 months - Tx:</B> 16/131 (12.2%)</P>
<P>
<B>Participants lost to follow-up during first 12 months - C:</B> 16/130 (12.3%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-21 01:21:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eskola-2001">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>This trial was part of a study including <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK> (FinOM Vaccine Trial). Both <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> and <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK> used the same control group (hepatitis B vaccine) but a different treatment group, each with a different type of 7-valent pneumococcal conjugate vaccine. <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> used a PCV7 containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to carrier protein CRM197, while <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK> used a PCV7 containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to the outer membrane protein complex of <I>N. meningitidis</I> serogroup B</P>
<P>
<B>Randomised -</B> yes, at individual level</P>
<P>
<B>Design -</B> standard parallel-group design</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes, both ITT and per-protocol analysis described</P>
<P>
<B>Follow-up - </B>22 consecutive months (children were followed up to 24 months of age)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 1662 healthy infants<BR/>
<B>Age - </B>2 months</P>
<P>
<B>Setting -</B> 8 study clinics in the communities of Tampere, Kangsala and Nokia, Finland</P>
<P>
<B>Inclusion criteria -</B> healthy children aged 2 months</P>
<P>
<B>Exclusion criteria -</B> not described</P>
<P>
<B>Baseline characteristics -</B> described and balanced (Table 1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine (PCV7) or a hepatitis B at 2, 4, 6 and 12 to 15 months of age</P>
<P>
<B>Tx -</B> PCV7 (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to carrier protein CRM197); N = 831 (N = 786 completed the follow-up as specified in the protocol)<BR/>
<B>C -</B> hepatitis B vaccine (containing 5 &#956;g of recombinant hepatitis B surface protein); N = 831 (N = 794 completed the follow-up as specified in the protocol)<BR/>
<B>Additional vaccines - </B>a combination vaccine containing whole-cell DTP and <I>Haemophilus influenzae </I>type B was given in the child's opposite thigh at the same visit as the pneumococcal vaccine at 2, 4 and 6 months of age. In half of the study clinics, the carrier protein in the DTP and <I>H. influenzae</I> vaccine was CRM197 and in the other half it was tetanus toxoid. Inactivated poliovirus vaccine was given at 7 months of age and again at the same time as the fourth dose of the study vaccine at 12 months of age. Measles&#8211;mumps&#8211;rubella vaccine was administered at 18 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:21:42 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>effect of PCV7 on the number of acute otitis media (AOM) episodes due to the pneumococcal serotypes included in the vaccine<BR/>
</P>
<P>
<B>Secondary outcomes -</B> effect of PCV7 on the number of all-cause AOM episodes, culture-confirmed AOM episodes and pathogen-specific AOM episodes, preventing first and subsequent AOM episodes, number of children with recurrent AOM episodes (defined as 3 or more AOM episodes in last 6 months or 4 or more in the last 12 months), serious adverse events</P>
<P>All children attended 1 of the study clinics for enrolment at 2 months of age and thereafter at 4, 6, 7, 12, 13, 18 and 24 months. Parents were encouraged to bring their child to the study clinic for evaluation of symptoms suggesting respiratory infection or AOM. AOM was diagnosed by otoscopy (visibly abnormal tympanic membrane in terms of colour, position or mobility, suggesting middle ear effusion) and the presence of at least 1 of the following symptoms or signs of acute infection: fever, earache, irritability, diarrhoea, vomiting, acute otorrhoea not caused by otitis externa and other symptoms of respiratory infection<BR/>For the overall and pathogen-specific AOM episodes, a new episode was considered to have started if at least 30 days had elapsed since the beginning of the previous episode. For AOM episodes according to serotype, a new episode was considered to have started if 30 days had elapsed since the beginning of an episode due to the same serotype, or if any interval had elapsed since the beginning of an episode due to a different serotype. If more than 1 serotype was recovered from the middle ear fluid at the same time, only 1 episode was considered to have started</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Participants lost to follow-up - total:</B> 82/1662 (4.9%) did not complete the follow-up period according to protocol</P>
<P>
<B>Participants lost to follow-up - Tx:</B> 45/831 (5.4%) did not complete the follow-up period according to protocol</P>
<P>
<B>Participants lost to follow-up - C:</B> 37/831 (4.5%) did not complete the follow-up period according to protocol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fireman-2003">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>This study is an extension of <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK> (data updated to 1999). Follow-up continued until children left Northern California Kaiser Permanente (NCKP) or until 20 April 1999, when the study was unblinded and the control group was offered PCV7. For a detailed description of the characteristics of this study, see <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-15 07:33:12 +1000" MODIFIED_BY="[Empty name]"/>
<CHAR_INTERVENTIONS MODIFIED="2013-11-15 07:33:12 +1000" MODIFIED_BY="[Empty name]"/>
<CHAR_OUTCOMES MODIFIED="2013-11-15 07:33:12 +1000" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2013-07-20 04:01:20 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-21 01:21:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jansen-2008">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, at individual level</P>
<P>
<B>Design -</B> standard parallel-group design</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Follow-up - </B>follow-up started 14 days after the second set of vaccinations and continued for 6 to 18 months, depending on the year of inclusion</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 597 children with a previously diagnosed respiratory tract infection (RTI)<BR/>
<B>Age - </B>18 to 72 months</P>
<P>
<B>Setting -</B> general practitioners (GPs) in the centre of the Netherlands selected children</P>
<P>
<B>Inclusion criteria -</B> children aged 18 to 72 months with a previously diagnosed respiratory tract infection (RTI) registered according to the International Classification of Primary Care (ICPC), i.e. acute otitis media (AOM); cough (with fever); acute upper RTI; acute laryngitis/tracheitis; acute bronchitis/bronchiolitis; influenza; pneumonia; pleurisy/pleural effusion</P>
<P>
<B>Exclusion criteria - </B>children with chronic asthma or recurrent wheezing (for longer than 3 months) treated with corticosteroids; craniofacial abnormalities; clinically significant hypersensitivity to eggs; previous serious adverse reactions to vaccines; previous influenza, pneumococcal or hepatitis B vaccinations and those with conditions for which these vaccinations are already recommended, such as chronic cardiac and respiratory conditions</P>
<P>
<B>Baseline characteristics -</B> described and balanced (Table 1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:19:59 +1000" MODIFIED_BY="[Empty name]">
<P>Children were randomly allocated to either trivalent influenza plus 7-valent pneumococcal conjugate vaccination (TIV/PCV7), trivalent influenza plus placebo vaccination (TIV/placebo) or hepatitis B virus vaccination plus placebo vaccination (HBV/placebo)</P>
<P>Children received 2 vaccinations 4 to 8 weeks apart in the first year of inclusion and the first 2 cohorts of children received a subsequent vaccination in the subsequent year</P>
<P>
<B>Tx -</B> TIV (strains in the 2003-2004 formulation were H1N1, H3N2 and B/HongKong/330/01; strains in the 2004-2005 formulation were H1N1, H3N2 and B/Shanghai/361/2002; strains in the 2005-2006 formulation included H1N1, H3N2 and B/Shanghai/361/2002/PCV7 (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to carrier protein CRM197); N = 197 (N = 163 completed; 67,867 person-days analysed, 14% missing)<BR/>
<B>C1 -</B> TIV/placebo (standard diluent (0.9% phosphate buffered NaCl)); N = 187 (N = 148 completed; 60,515 person-days analysed, 20% missing)</P>
<P>
<B>C2 -</B> HBV (recombinant HBV vaccine; Engerix-B Junior)/placebo; N = 195 (N = 160 completed; 67,679 person-days analysed, 15% missing)<BR/>
<B>Additional vaccines - </B>not described<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>effect of the TIV/PCV7 on febrile RTI, defined as fever (tympanic temperature 38.0 C) for at least 2 consecutive days accompanied by 1 or more of the aforementioned signs or symptoms of RTI with a moderate or severe severity score<BR/>
</P>
<P>
<B>Secondary outcomes -</B> effect of the TIV/PCV7 on febrile RTI&#8211;related polymerase chain reaction (PCR)-confirmed influenza, GP visits, antibiotic prescriptions or a physician-diagnosed episode of AOM</P>
<P>Each parent was instructed to keep a daily diary, recording any clinical signs or symptoms associated with RTI and to characterise their severity on a scale of 1 (mild) to 3 (severe). The parent also was instructed to measure the child's body temperature using a validated electronic tympanic thermometer. The parent also was asked to record all GP visits due to their child's RTI-related complaints. For each such visit, the GP was instructed to complete a form including information on the diagnosis and possible antibiotic prescriptions<BR/>During influenza seasons, the parent was instructed to contact the trial centre for evaluation for influenza if the child had fever (tympanic temperature 38.0 C) for more than 1 day accompanied by at least 1 RTI-associated sign or symptom of severity score 2. Within 4 days of onset of fever and symptoms, a trained research assistant obtained a nasopharyngeal swab for viral determination. Each sample was analysed by real-time PCR for the presence of influenza A and B viruses</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-21 01:21:52 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Participants lost to follow-up - total:</B> 108/579 (18.7%) completely (n = 41) or partially (n = 67) lost to follow-up</P>
<P>
<B>Participants lost to follow-up - Tx:</B> 34/197 (17.3%) completely (n = 8) or partially (n = 26) lost to follow-up; 67,867 person-days analysed, 14% missing</P>
<P>
<B>Participants lost to follow-up - C1:</B> 39/187 (20.8%) completely (n = 19) or partially (n = 20) lost to follow-up; 60,515 person-days analysed, 20% missing</P>
<P>
<B>Participants lost to follow-up - C2:</B> 35/195 (17.9%) completely (n = 14) or partially (n = 21) lost to follow-up; 67,679 person-days analysed, 15% missing</P>
<P>2 of the 3 treatment arms received an additional vaccination in the second year of the study. To evaluate blinding, parents of these cohorts of children were asked which vaccinations that they thought their child had received just after the vaccinations were given and at the end of the study. Just after the vaccination, 87% of the parents either did not know or identified the wrong set of vaccinations; at the end of the study, this percentage was 80%, indicating successful blinding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-24 21:49:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kilpi-2003">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>This trial was part of a study including <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> (FinOM Vaccine Trial). Both <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> and <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK> used the same control group (hepatitis B vaccine) but a different treatment group, each with a different type of 7-valent pneumococcal conjugate vaccine. <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> used a PCV7 containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to carrier protein CRM197, while <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK> used a PCV7 containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to the outer membrane protein complex of <I>N. meningitidis</I> serogroup B</P>
<P>
<B>Randomised -</B> yes, at individual level</P>
<P>
<B>Design -</B> standard parallel-group design</P>
<P>
<B>Intention-to-treat (ITT) -</B> no, per-protocol analysis</P>
<P>
<B>Follow-up - </B>22 consecutive months (children were followed up to 24 months of age)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-27 14:34:28 +1000" MODIFIED_BY="Liz Dooley">
<P>
<B>N -</B> 1666 healthy infants<BR/>
<B>Age - </B>2 months</P>
<P>
<B>Setting -</B> 8 study clinics in the communities of Tampere, Kangsala and Nokia, Finland</P>
<P>
<B>Inclusion criteria -</B> healthy children aged 2 months</P>
<P>
<B>Exclusion criteria -</B> not described</P>
<P>
<B>Baseline characteristics -</B> described and balanced (Table 1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-24 21:49:05 +1000" MODIFIED_BY="[Empty name]">
<P>Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine (PCV7) or a hepatitis B at 2, 4, 6 and 12 to 15 months of age. From 3 November 1997 onward, for the children randomised to receive OMPC-PCV7, the fourth dose of the conjugate vaccine was replaced by a 23-valent pneumococcal polysaccharide vaccine (PPV-23) that consisted of serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F (Pneumovax23)</P>
<P>
<B>Tx -</B> PCV7 (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to the outer membrane protein complex of <I>N. meningitidis</I> serogroup B (OMPC)); N = 835 (N = 805 completed the follow-up as specified in the protocol)<BR/>
<B>C -</B> hepatitis B vaccine (containing 5 &#956;g of recombinant hepatitis B surface protein); N = 831 (N = 794 completed the follow-up as specified in the protocol)<BR/>
<B>Additional vaccines - </B>a diphtheria&#8211;tetanus toxoids&#8211;pertussis vaccine with a whole-cell pertussis component, combined with a <I>Haemophilus influenzae</I> type b conjugate vaccine (DTP-Hib), was administered concomitantly with the first 3 doses of the study vaccine and an inactivated poliovirus vaccine was administered with the fourth dose. In 4 study clinics, the carrier protein in the DTP-Hib conjugate combination was CRM197 and in the other 4 it was tetanus toxoid<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-15 07:33:13 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Participants lost to follow-up - total:</B> 67/1,666 (4.0%) did not complete the follow-up period according to protocol</P>
<P>
<B>Participants lost to follow-up - Tx:</B> 30/835 (3.6%) did not complete the follow-up period according to protocol</P>
<P>
<B>Participants lost to follow-up - C:</B> 37/831 (4.5%) did not complete the follow-up period according to protocol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Brien-2008">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>The design of this cluster-randomised trial has been described extensively in <LINK REF="REF-Moulton-2001" TYPE="REFERENCE">Moulton 2001</LINK>, while the findings on invasive pneumococcal disease (main outcome of the trial) have been published in <LINK REF="REF-O_x0027_Brien-2003" TYPE="REFERENCE">O'Brien 2003</LINK>
</P>
<P>
<B>Randomised -</B> yes, at group level</P>
<P>
<B>Design -</B> cluster-randomised design</P>
<P>
<B>Intention-to-treat (ITT) -</B> no, per-protocol analysis</P>
<P>
<B>Follow-up - </B>depending on time of inclusion, maximum duration of follow-up 40 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-09 10:32:42 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 944 (944 of the 4476 children were randomly selected for chart review. This sample size was determined by logistic feasibility and expected frequency of healthcare events. Of these 944 children, 856 were found to have strictly met the chart review criteria)<BR/>
<B>Age - </B>below 2 years of age</P>
<P>
<B>Setting -</B> Navajo and White Mountain Apache region</P>
<P>
<B>Inclusion criteria -</B> Navajo and White Mountain Apache children below 2 years of age</P>
<P>
<B>Exclusion criteria -</B> no exclusion criteria described</P>
<P>
<B>Baseline characteristics -</B> balanced but data not shown</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine (PCV7) or a meningococcus type C conjugate vaccine (MenC). For each of the study and control vaccines, 3 immunisation schedules were designed according to age of entry into the trial: 6 weeks to 6 months (3 doses, ideally at 2, 4 and 6 months of age and a booster at 12 to 15 months of age), 7 months to 11 months (2 doses 1 month apart and a booster at 12 to 15 months of age) and 12 months to 23 months (2 doses separated by at least 2 months). Over the course of the trial, the great majority of new enrollees are in the first group, which is referred to as the primary efficacy cohort</P>
<P>
<B>Tx -</B> PCV7 (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to carrier protein CRM197); N = unknown (N = 424 analysed in primary efficacy group)<BR/>
<B>C -</B> MenC (10 G of group C oligosaccharide conjugated to carrier protein CRM197); N = unknown (N = 432 analysed in primary efficacy group)<BR/>
<B>Additional vaccines - </B>not described<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>effect of PCV7 on clinically diagnosed episodes of OM<BR/>Every medical visit made by study children was evaluated through 2 years of age. OM visits, as documented by the patients' treating physician, were recorded</P>
<P>A new OM episode was counted if any of the following were recorded as the diagnosis: OM, AOM, bilateral OM, chronic OM, OM with perforation, otorrhoea, pressure equalising tube placement, perforated tympanic membrane, serous OM and bullous myringitis</P>
<P>An episode of AOM was categorised as either AOM or bilateral AOM. An OM episode was categorised as severe if there were 3 or more OM visits for the episode. A child's first medical visit for OM was considered their first episode. OM visits occurring less than 21 days after the immediately prior otitis-related visit and visits noted as a follow-up to a previous otitis-related visit were counted as follow-up visits, not as OM episodes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Participants lost to follow-up - total:</B> 88/944 (9.3%) not included in primary efficacy analysis</P>
<P>
<B>Participants lost to follow-up - Tx:</B> unknown</P>
<P>
<B>Participants lost to follow-up - C:</B> unknown</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palmu-2009">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>This study is an additional analysis of <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>, which is part of the FinOM Vaccine Trial and studies the effect of PCV7 containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to carrier protein CRM197 as compared to a hepatitis B vaccine. For a detailed description of the characteristics of this study, see <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:11:50 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>effect of PCV7 on PCR-positive AOM<BR/>The aetiology of AOM attacks was determined by bacterial culture of middle ear fluid samples obtained by myringotomy. In addition, PCR was performed from the middle ear fluid samples. Samples with a positive PCR result were reanalysed using Ply-PCR followed by microwell hybridisation using a Europium-labelled probe<BR/>Definitions of 30-day episodes were used in the analysis, for example, a new episode of PCR-positive AOM was considered to start if 30 days had elapsed since the start of the previous PCR-positive AOM episode</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-20 05:40:19 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prymula-2006">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, at individual level</P>
<P>
<B>Design -</B> standard parallel-group design</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes, both ITT and per-protocol analysis described</P>
<P>
<B>Follow-up - </B>efficacy follow-up started on the day of the first dose of study vaccine (for ITT analysis) or 2 weeks after the third vaccine dose (for the per-protocol analysis) and continued until 24 to 27 months of age</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 4968 healthy infants<BR/>
<B>Age - </B>between 6 weeks and 5 months</P>
<P>
<B>Setting -</B> 27 paediatric centres in the Czech Republic and 23 in Slovakia</P>
<P>
<B>Inclusion criteria -</B> healthy children aged between 6 weeks and 5 months with no acute illness</P>
<P>
<B>Exclusion criteria -</B> use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the study vaccines' first dose; previous vaccination against <I>S. pneumoniae</I>; fever (defined as a rectal temperature of 38 C or higher or temperature by other routes of 37.5 C or higher); history of allergic disease or reactions likely to be exacerbated by any component of the study vaccines; other conditions that might have potentially interfered with the interpretation of study outcomes according to the investigator</P>
<P>
<B>Baseline characteristics -</B> described and balanced (Table 1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Children were randomly allocated to either an 11-valent pneumococcal conjugate vaccine (PCV11) or a hepatitis A at the ages of about 3, 4, 5 and 12 to 15 months of age</P>
<P>
<B>Tx -</B> PCV11 (containing the polysaccharides of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F conjugated to protein D (surface lipoprotein of <I>H. influenzae</I>)); N = 2489 (N = 2455 included in per-protocol cohort for efficacy)<BR/>
<B>C -</B> hepatitis A vaccine (containing 720 ELISA units of inactivated hepatitis A virus antigen (strain HM 175)); N = 2479 (N = 2452 included in per-protocol cohort for efficacy)<BR/>
<B>Additional vaccines - </B>a concomitant hexavalent diphtheria-tetanus-3-component acellular pertussis-hepatitis B-inactivated poliovirus types 1, 2 and 3 <I>H. influenzae</I> type b (DTPa-HBV-IPV/Hib) vaccine was offered to all study participants, followed by a booster dose at age 15 to 18 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>effect of PCV11 on first episode of acute otitis media (AOM) caused by vaccine pneumococcal serotypes<BR/>
</P>
<P>
<B>Secondary outcomes -</B> effect of PCV11 on first episode of AOM caused by non-typeable <I>Haemophilus influenzae</I>
</P>
<P>There was no active surveillance. Unscheduled doctor visits could take place any time during follow-up according to standard local practice (parents consulting their local paediatrician in case of illness of their child). Parents were advised to consult their paediatrician if their child was sick, had ear pain or had spontaneous ear discharge. Children with suspected AOM were immediately referred to ENT surgeons</P>
<P>AOM was defined as either abnormal findings of the tympanic membrane at otoscopy (i.e. redness, bulging, loss of light reflex) or the presence of middle ear effusion as shown by simple or pneumatic otoscopy or by microscopy together with at least 2 of the following signs or symptoms: ear pain, ear discharge, hearing loss, fever, lethargy, irritability, anorexia, vomiting or diarrhoea. These signs or symptoms had to be present for a maximum of 14 days</P>
<P>For patients with repeated doctor visits, a new episode of AOM was judged to have started if more than 30 days had elapsed since the beginning of the previous episode. Additionally, for categories defined according to bacterial pathogen or serotype, a new episode was judged to have started if any interval had elapsed since the beginning of an episode caused by a different bacterial pathogen or serotype</P>
<P>Recurrent AOM was defined as 3 or more AOM episodes in the last 6 months or 4 or more in the last 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Participants lost to follow-up - total:</B> 61/4968 (1.2%) did not complete the follow-up period according to protocol</P>
<P>
<B>Participants lost to follow-up - Tx:</B> 34/2489 (1.4%) did not complete the follow-up period according to protocol</P>
<P>
<B>Participants lost to follow-up - C:</B> 27/2479 (1.1%) did not complete the follow-up period according to protocol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Kempen-2006">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>This study was performed in parallel with <LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>, but analysed separately due to differences in study population</P>
<P>
<B>Randomised -</B> yes, at individual level</P>
<P>
<B>Design -</B> standard parallel-group design</P>
<P>
<B>Intention-to-treat (ITT) -</B> unclear</P>
<P>
<B>Follow-up - </B>26 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 74 children with a history of frequent acute otitis media (AOM)<BR/>
<B>Age - </B>between 1 and 7 years</P>
<P>
<B>Setting -</B> ENT department of the Ghent University Hospital in Belgium</P>
<P>
<B>Inclusion criteria -</B> children aged 1 to 7 years with a history of frequent AOM defined as at least 2 separate clinically diagnosed AOM episodes in the past year</P>
<P>
<B>Exclusion criteria -</B> children with any underlying illnesses including immunocompromising conditions other than partial serum IgA and IgG2 deficiencies, craniofacial abnormalities, previous pneumococcal vaccination or documented hypersensitivity to any of the vaccine components</P>
<P>
<B>Baseline characteristics -</B> described and balanced (Table 1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine (PCV7) or a hepatitis A vaccine. Children aged 12 to 24 months received 2 intramuscular injections with a 1-month interval and those aged over 2 years received 1 intramuscular injection. Those allocated to PCV7 received an additional 23-valent pneumococcal polysaccharide vaccination (PPSV-23) respectively at 6 months (in children aged 12 to 24 months) and 7 months (in those aged above 2 years) later</P>
<P>
<B>Tx -</B> PCV7 (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to the carrier protein CRM197)/PPSV23 (containing polysaccharides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F); N = 38 (N = 35 completed the vaccination scheme)<BR/>
<B>C -</B> hepatitis A vaccine (containing 720 units of inactivated hepatitis A virus); N = 36 (N = 33 completed the vaccination scheme)<BR/>
<B>Additional vaccines - </B>not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>effect of PCV7/PPSV23 on the number of AOM episodes during 18 months follow-up<BR/>
</P>
<P>
<B>Secondary outcomes -</B> effect of PCV7/PPSV23 on immunogenicity; nasopharyngeal carriage of conjugate vaccine related serotypes; and antibiotic-resistant pneumococci</P>
<P>At scheduled hospital visits at 7, 14, 20 and 26 months after randomisation, a medical history was taken, antibiotic usage noted and an otomicroscopic examination performed<BR/>When, at least 1 month following complete vaccination, a new AOM episode was suspected, parents were asked to bring their sick child within 24 hours to the study centre for otoscopic diagnosis. In case of all other AOM episodes during follow-up, participants were allowed to visit the study centre, their family physician or a paediatrician who was asked to report otoscopic findings, diagnosis and treatment on an AOM registration form</P>
<P>AOM was defined by an abnormal tympanic membrane on otomicroscopy (red, dull or bulging); plus at least 1 of the following symptoms or signs of acute infection: earache, acute otorrhoea, fever (&gt; 38.5 C rectally) or irritability</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Participants lost to follow-up - total:</B> 6/74 (8.1%) did not complete the follow-up period according to protocol</P>
<P>
<B>Participants lost to follow-up - Tx:</B> 3/38 (7.9%) did not complete the follow-up period according to protocol</P>
<P>
<B>Participants lost to follow-up - C:</B> 3/36 (8.3%) did not complete the follow-up period according to protocol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veenhoven-2003">
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, at individual level</P>
<P>
<B>Design -</B> standard parallel-group design</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Follow-up - </B>18 months, starting 1 month after completion of the vaccination scheme</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 383 children with a history of frequent acute otitis media (AOM)<BR/>
<B>Age - </B>between 1 and 7 years</P>
<P>
<B>Setting -</B> a general hospital (Spaarne Hospital, Haarlem) and a tertiary care hospital (Wilhelmina Children's Hospital of the University Medical Centre Utrecht) in the Netherlands</P>
<P>
<B>Inclusion criteria -</B> children aged 1 to 7 years with a history of frequent AOM defined as 2 or more AOM episodes in the year before study entry. The number of previous AOM episodes was based on parental report and on clinical confirmation of the diagnosis by a physician</P>
<P>
<B>Exclusion criteria -</B> children with immunodeficiency, cystic fibrosis, immotile cilia syndrome, craniofacial abnormalities, chromosomal abnormalities such as Down's syndrome and severe adverse events during previous vaccinations</P>
<P>
<B>Baseline characteristics -</B> described and balanced (Table 1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Children were randomly allocated to either a 7-valent pneumococcal conjugate vaccine (PCV7) followed by a 23-valent pneumococcal polysaccharide vaccination (PPSV23) or a hepatitis A or B vaccine</P>
<P>Children aged 12 to 24 months in the pneumococcal vaccination group received PCV7 twice with a 1-month interval followed 6 months later by PPSV23. The control vaccine group received 3 hepatitis B vaccinations according to a similar time schedule</P>
<P>Children aged 25 to 84 months in the pneumococcal vaccine group received 1 dose of PCV7 followed 7 months later by PPSV23. The control group received hepatitis A vaccine twice</P>
<P>
<B>Tx -</B> PCV7 (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to the carrier protein CRM197)/PPSV23 (containing polysaccharides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F); N = 190 (N = 190 included in ITT analysis)<BR/>
<B>C -</B> hepatitis A vaccine (Havrix) or hepatitis B vaccine (Engerix-B); N = 193 (N = 193 included in ITT analysis)<BR/>
<B>Additional vaccines - </B>not described.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>effect of PCV7/PPSV23 on the number of clinical episodes of AOM during 18 months follow-up<BR/>
</P>
<P>
<B>Secondary outcomes -</B> effect of PCV7/PPSV23 on the number of AOM episodes due to the 7 pneumococcal serotypes included in the PCV7 vaccine and nasopharyngeal carriage of conjugate vaccine serotypes</P>
<P>Parents were instructed to visit the study clinics or their family physician, otolaryngologist or paediatrician to assess symptoms suggesting AOM. Physicians registered signs and symptoms of every AOM episode on standard registration forms and were unaware of treatment allocation. AOM was defined according to the guideline issued by the Dutch College of General Practitioners, i.e. presence of an abnormal tympanic membrane on otoscopy (red, dull or bulging), or otorrhoea and at least 1 of these signs or symptoms of acute infection: acute earache, new-onset otorrhoea, irritability or fever greater than 38.5 C rectally or 38.0 C axillary</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Participants lost to follow-up - total:</B> 1/383 (0.3%); all children included in ITT analysis</P>
<P>
<B>Participants lost to follow-up - Tx:</B> 0/190 (0%)</P>
<P>
<B>Participants lost to follow-up - C:</B> 1/193(0.5%)</P>
<P>Performed in parallel with the study of <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>, but analysed separately due to differences in study population</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Ab: antibiotics; AOM: acute otitis media; C: control; DCC: day-care centre; DTaP: diphtheria-tetanus toxoid-acellular pertussis vaccine; DTP: diphtheria-tetanus toxoid-pertussis vaccine; DTwP: diphtheria-tetanus toxoid-whole cell pertussis vaccine; ENT: ear, nose and throat; IgA: immunoglobulin A; IgG: immunoglobulin G; GP: general practitioner; ITT: intention-to-treat; NaCl: sodium chloride; OM: otitis media; PCR: polymerase chain reaction; PCV: pneumococcal conjugate vaccine; PPV: pneumococcal polysaccharide vaccine; RTI: respiratory tract infection; TIV: trivalent influenza vaccine; Tx: treatment<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gisselsson-Solen-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>No control vaccination. As such, parents were not blinded to treatment allocation (children received either PCV or no vaccination). However, for outcome assessment, parents were instructed to visit the ENT department whenever they suspected an episode of AOM. Parental threshold to consult ENT may be lower in children allocated to control treatment (no vaccination) than in those allocated to PCV, which may have introduced (detection) bias</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-25 11:41:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jokinen-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-25 11:41:34 +1000" MODIFIED_BY="[Empty name]">
<P>Re-analysis of the <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> study without new outcome data that could be used for our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-25 11:41:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-25 11:41:37 +1000" MODIFIED_BY="[Empty name]">
<P>RCT studying the effect of PCV on OME</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-05 11:54:19 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Roy-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-05 11:54:19 +1000" MODIFIED_BY="Liz Dooley">
<P>RCT studying the effect of PCV on suppurative otitis media (abstract of conference meeting)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AOM: acute otitis media<BR/>ENT: ear, nose and throat<BR/>OME: otitis media with effusion<BR/>PCV: pneumococcal conjugate vaccine<BR/>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-07-20 01:05:18 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-03-21 01:19:24 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-03-21 01:19:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00466947">
<CHAR_STUDY_NAME MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>'COMPAS: Phase III, Double-blind, Randomized Study to Demonstrate Efficacy of GSK Biologicals' Pneumococcal Conjugate Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media (AOM)'</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-03-21 01:19:24 +1000" MODIFIED_BY="[Empty name]">
<P>Phase III, double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-15 07:33:18 +1000" MODIFIED_BY="[Empty name]">
<P>Healthy children aged 6 to 16 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Group A: pneumococcal conjugate vaccine GSK1024850A 4 doses, hepatitis A vaccine 2 doses, DTaP-IPV/Hib vaccine 1 dose Group B: hepatitis A vaccine 3 doses, hepatitis B vaccine 3 doses, DTaP-IPV/Hib vaccine 4 doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: occurrence of likely bacterial community-acquired pneumonia (CAP) cases<BR/>Secondary outcomes include occurrence of clinically confirmed acute otitis media (AOM) cases (in a subset), occurrence of bacteriologically confirmed AOM cases (B-AOM) caused by any bacterial pathogen (in a subset), bacteriologically confirmed AOM cases (B-AOM) caused by vaccine serotypes, cross-reactive and other pneumococcal serotypes (in a subset)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>June 2007; study complete date: June 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-03-21 00:27:24 +1000" MODIFIED_BY="[Empty name]">
<P>GSK Clinical Trials Call Centre<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-11-15 07:33:18 +1000" MODIFIED_BY="[Empty name]">
<P>NCT00466947</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00861380">
<CHAR_STUDY_NAME MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>'Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (FinIP)'</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-11-15 07:33:18 +1000" MODIFIED_BY="[Empty name]">
<P>Cluster-randomised, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-15 07:33:19 +1000" MODIFIED_BY="[Empty name]">
<P>Healthy children aged younger than 19 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Infants aged younger than 7 months at the first vaccination received either a 3+1 or a 2+1 vaccination schedule, children aged 7 to 11 months received a 2+1 schedule and those 12 to 18 months of age received a 2-dose schedule. Children received PD-CV10 in 52 clusters or hepatitis vaccines as control in 26 clusters<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: occurrence of culture-confirmed pneumococcal invasive diseases due to any of the vaccine-related pneumococcal serotypes<BR/>Secondary outcomes include occurrence of tympanostomy tube placements, occurrence of upper and lower respiratory tract infections, including AOM (in a subset of vaccinated subjects in Turku area)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>March 2009; study complete date: January 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-03-21 00:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>GSK Clinical Trials Call Centre</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-12-09 10:46:38 +1000" MODIFIED_BY="[Empty name]">
<P>NCT00861380; published papers: effect PD-CV10 on primary outcome (<LINK REF="REF-Palmu-2013a" TYPE="REFERENCE">Palmu 2013a</LINK>) and secondary outcome, i.e. outpatient antimicrobial purchases (<LINK REF="REF-Palmu-2013b" TYPE="REFERENCE">Palmu 2013b</LINK>)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01174849">
<CHAR_STUDY_NAME MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>'A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes'</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-15 07:33:20 +1000" MODIFIED_BY="[Empty name]">
<P>Indigenous infants 4 to 6 weeks of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>3 doses of either PCV13 or PD-CV10 versus an early schedule of a combination of 3 doses of PD-CV10 and 1 dose of PCV13</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: immunogenicity<BR/>Secondary outcomes: nasopharyngeal carriage, otitis media</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-11-15 07:33:20 +1000" MODIFIED_BY="[Empty name]">
<P>August 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-11-15 07:33:20 +1000" MODIFIED_BY="[Empty name]">
<P>Amanda J Leach, PhD; Menzies School of Health Research, Darwin, Northern Territory, Australia, 0810</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-11-15 07:33:20 +1000" MODIFIED_BY="[Empty name]">
<P>NCT01174849</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01545375">
<CHAR_STUDY_NAME MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>'Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children: Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants'</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-03-21 00:29:28 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>A healthy American Indian infant between and including 6 and 12 weeks (42 to 90 days) of age at the time of the first vaccination</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:14:39 +1000" MODIFIED_BY="[Empty name]">
<P>GSK2189242A vaccine versus placebo co-administration of PCV13 and Hib-CV. Hib-CV will be given as study vaccine for infants of the immuno/reacto subgroup; for the other infants, this vaccine will be given as part of the routine vaccination schedule</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: occurrence of any clinical AOM episodes diagnosed and verified against American Academy of Pediatrics (AAP) criteria<BR/>Secondary outcomes include occurrence of any healthcare provider-diagnosed clinical AOM, occurrence of any clinical AOM episodes diagnosed and verified against modified AAP criteria, occurrence of any recurrent AOM (at least 3 episodes in 6 months or at least 4 episodes in 12 months).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-11-15 07:33:19 +1000" MODIFIED_BY="[Empty name]">
<P>May 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-11-15 07:33:19 +1000" MODIFIED_BY="[Empty name]">
<P>GSK Clinical Trials Call Center</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-11-15 07:33:19 +1000" MODIFIED_BY="[Empty name]">
<P>NCT01545375<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01735084">
<CHAR_STUDY_NAME MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>'Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections'</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Single-blind (outcomes assessor), randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Australian indigenous infants who were participants in PREV-IX_COMBO trial of primary course pneumococcal conjugate vaccines, age at least 2 months post final dose of primary course</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-21 01:14:42 +1000" MODIFIED_BY="[Empty name]">
<P>PCV13 versus PD-CV10</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: immune response<BR/>Secondary outcomes: nasopharyngeal carriage, any otitis media, episodes of respiratory illness and acute otitis media</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-11-15 07:33:20 +1000" MODIFIED_BY="[Empty name]">
<P>December 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-11-15 07:33:20 +1000" MODIFIED_BY="[Empty name]">
<P>Amanda J Leach, PhD; Menzies School of Health Research, Darwin, Northern Territory, Australia, 0810 </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-11-15 07:33:20 +1000" MODIFIED_BY="[Empty name]">
<P>NCT01735084<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>AAP: American Academy of Pediatrics<BR/>AOM: acute otitis media<BR/>DTaP-IPV/Hib: diphtheria-tetanus toxoid-acellular pertussis-inactivated polio-haemophilus influenzae type B vaccine<BR/>Hib-CV: haemophilus influenzae type B conjugate vaccine</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-03-24 21:50:12 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>Method of random sequence generation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dagan-2001">
<DESCRIPTION>
<P>Method of random sequence generation not described. Block randomisation (n = 6) stratified by DCC and age</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-25 11:19:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>6 letters corresponding to the 3 treatment options were randomly allocated to consecutive subject identification numbers, using an allocation of 1:1:1 and a block size of 12 (see <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-25 11:20:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fireman-2003">
<DESCRIPTION>
<P>This study is an extension of <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>
</P>
<P>Method of random sequence generation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jansen-2008">
<DESCRIPTION>
<P>Method of random sequence generation not described; children were randomly assigned in blocks of 3 in a 1:1:1 ratio</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-25 11:25:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>6 letters corresponding to the 3 treatment options were randomly allocated to consecutive subject identification numbers, using an allocation of 1:1:1 and a block size of 12</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2008">
<DESCRIPTION>
<P>Computer-generated randomisation using 38 independent randomisation units, stratified using 3 blocks of 4 units and 13 blocks of 2 units</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-25 11:29:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palmu-2009">
<DESCRIPTION>
<P>This is an additional analysis of <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>
</P>
<P>6 letters corresponding to the 3 treatment options were randomly allocated to consecutive subject identification numbers, using an allocation of 1:1:1 and a block size of 12</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prymula-2006">
<DESCRIPTION>
<P>Computer-generated random list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 00:09:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Kempen-2006">
<DESCRIPTION>
<P>Method of random sequence generation not described, randomisation stratified according to age (12 to 24 months versus 25 to 84 months) and number of previous AOM episodes per year (2 to 3 versus 4 or more episodes)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 00:13:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veenhoven-2003">
<DESCRIPTION>
<P>Table of random numbers that identified the vaccine scheme, randomisation stratified according to age (12 to 24 months versus 25 to 84 months) and number of previous AOM episodes per year (2 to 3 versus 4 or more episodes)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-03-24 21:50:12 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>No method of allocation concealment was described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dagan-2001">
<DESCRIPTION>
<P>Randomisation list provided in a sealed envelope by Wyeth-Lederle Vaccines</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>Individual treatment assignments were kept in sealed envelopes until vaccination (see <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fireman-2003">
<DESCRIPTION>
<P>No method of allocation concealment was described </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jansen-2008">
<DESCRIPTION>
<P>No method of allocation concealment was described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>Individual treatment assignments were kept in sealed envelopes until vaccination</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-24 21:50:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2008">
<DESCRIPTION>
<P>6 labels were assigned to the vaccines (B, F, H, M, T, U), with 3 labels for PCV7 and 3 for MenC. The grouping of these codes was known only to a statistician employed by the manufacturer (who had no other responsibilities with respect to the trial other than handling treatment allocation and randomisation issues. No loss of clusters</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palmu-2009">
<DESCRIPTION>
<P>Individual treatment assignments were kept in sealed envelopes until vaccination</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prymula-2006">
<DESCRIPTION>
<P>Randomisation (1:1) was done with a study-specific central randomisation system via the Internet which, on receipt of the infant's initials and birth date, determined the vaccine number to be used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 00:10:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Kempen-2006">
<DESCRIPTION>
<P>2 study nurses immunised all children according to a randomisation list provided to them in a sealed envelope by a third party (the Julius Center for Health Sciences, Utrecht, The Netherlands)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veenhoven-2003">
<DESCRIPTION>
<P>No method of allocation concealment was described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-07-17 20:45:39 +1000" MODIFIED_BY="Liz Dooley" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-03-21 01:15:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>Indicated to be double-blind study but insufficient details provided to ensure blinding of participants and personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dagan-2001">
<DESCRIPTION>
<P>Appearance of PCV9 and MenC vaccines was not similar. 2 nurses not belonging to the study team injected the vaccines. They were not allowed reveal the child's allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>Use of vaccinators who were not otherwise involved in the trial follow-up. Letter code was destroyed immediately after vaccination (see <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-03-21 01:16:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fireman-2003">
<DESCRIPTION>
<P>Indicated to be double-blind study but insufficient details provided to ensure blinding of participants and personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jansen-2008">
<DESCRIPTION>
<P>The injections were administered by non-blinded research nurses who were not involved in subsequent follow-up and were instructed to not reveal the intervention allocation. The treatment group assignments were not revealed to parents, investigators, research personnel conducting the follow-up or health care providers, all of whom remained blinded throughout the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>Use of vaccinators who were not otherwise involved in the trial follow-up. Letter code was destroyed immediately after vaccination</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-27 14:34:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2008">
<DESCRIPTION>
<P>Masked treatment assignment (vaccines were labelled). In addition, field staff were blinded as to serotype of the invasive disease cases and thus did not know which ones would be likely to be prevented by an effective vaccine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palmu-2009">
<DESCRIPTION>
<P>Use of vaccinators who were not otherwise involved in the trial follow-up. Letter code was destroyed immediately after vaccination</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prymula-2006">
<DESCRIPTION>
<P>Indicated to be double-blinded study. Sponsor numbered the vaccine supplies. It was, however, unknown whether the appearance of the vaccines was similar at the time of administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Kempen-2006">
<DESCRIPTION>
<P>The nurses that vaccinated children were not allowed to reveal the child's allocation to either the study team or the parents</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veenhoven-2003">
<DESCRIPTION>
<P>Vaccine was administered to the child by a study nurse, so that parents and physicians were unaware of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-15 07:33:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>Clinical diagnoses of AOM were obtained from computerised data sources using diagnoses registered by emergency physicians and paediatricians (non-trialists)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-15 07:33:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dagan-2001">
<DESCRIPTION>
<P>Parental interview. A positive report of OM was defined as an episode</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>Assessment of the outcome was done according to a strict definition of AOM. Assessment was done by other personnel than those that vaccinated the children (vaccinators were not otherwise involved in the trial follow-up) (see <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-25 11:20:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fireman-2003">
<DESCRIPTION>
<P>Clinical diagnoses of AOM were obtained from computerised data sources using diagnoses registered by emergency physicians and paediatricians (non-trialists)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jansen-2008">
<DESCRIPTION>
<P>The parents were asked to record all GP visits due to their child's RTI-related complaints. For each such visit, the GP was instructed to complete a form including information on the diagnosis and possible antibiotic prescriptions. The treatment group assignments were not revealed to parents, investigators, research personnel conducting the follow-up or health care providers, all of whom remained blinded throughout the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>Assessment of the outcome was done according to a strict definition of AOM. Assessment was done by other personnel than those who vaccinated the children (vaccinators were not otherwise involved in the trial follow-up)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-2008">
<DESCRIPTION>
<P>Every medical visit made by study children was evaluated through 2 years of age. OM visits, as documented by the patients' treating physician, were recorded. Treating physicians were blinded to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palmu-2009">
<DESCRIPTION>
<P>Assessment of the outcome was done according to a strict definition of AOM. Assessment was done by other personnel than those that vaccinated the children (vaccinators were not otherwise involved in the trial follow-up)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-15 07:33:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prymula-2006">
<DESCRIPTION>
<P>Visits during efficacy follow-up were according to standard local clinical practice. When AOM was suspected children were referred to ENT surgeons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Kempen-2006">
<DESCRIPTION>
<P>When a new AOM episode was suspected, parents were asked to bring their sick child within 24 hours to the study centre for otoscopic diagnosis. In case of all other AOM episodes during follow-up, participants were allowed to visit the study centre, their family physician or a paediatrician who was asked to report otoscopic findings, diagnosis and treatment on an AOM registration form</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veenhoven-2003">
<DESCRIPTION>
<P>Parents were instructed to visit the study clinics or their family physician, otolaryngologist or paediatrician to assess symptoms suggesting AOM. Physicians registered signs and symptoms of every AOM episode on standard registration forms and were unaware of treatment allocation. AOM was defined according to the guideline issued by the Dutch College of General Practitioners</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-15 07:33:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>Unclear how many children were included in otitis media analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dagan-2001">
<DESCRIPTION>
<P>Follow-up rates reported in Table 1. 12% of children followed up for &lt; 12 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-21 01:11:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>No reporting of reasons for drop-out and/or lost to follow-up. Not expected to have major impact on outcome since 94.6% in the PCV7 and 95.5% in the control group completed the follow-up as specified in the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fireman-2003">
<DESCRIPTION>
<P>Substantial number of randomised children did not stay in the Kaiser Permanente healthcare database to the end of follow-up (April 1999), i.e. 27% in the PCV group and 26% in the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jansen-2008">
<DESCRIPTION>
<P>Substantial loss to follow-up (&lt; 14% in both groups)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>No reporting of reasons for drop-out and/or loss to follow-up. Not expected to have a major impact on outcome since 96.0% in the PCV7 OMPC and 95.5% in the control group completed the follow-up as specified in the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-15 07:33:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-2008">
<DESCRIPTION>
<P>88 of the 944 children (9.3%) not included in primary efficacy analysis; no information provided on the distribution across treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palmu-2009">
<DESCRIPTION>
<P>Unclear how many children were lost to follow-up. In <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>, 94.6% in the PCV7 and 95.5% in the control group completed the follow-up as specified in the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prymula-2006">
<DESCRIPTION>
<P>No reporting of reasons for drop-out and/or loss to follow-up. Not expected to have a major impact on outcome since 98.6% in the PCV11 and 98.9% in the control group completed the follow-up as specified in the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Kempen-2006">
<DESCRIPTION>
<P>In total 6 of the 74 children (8.1%) did not complete the follow-up period according to protocol (equally distributed across groups). Reasons for withdrawals are described in the Results section of the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-21 00:14:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veenhoven-2003">
<DESCRIPTION>
<P>All randomised children were included in ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>Study protocol is not available. Otitis media endpoint (efficacy against otitis media episodes) is reported as a secondary endpoint</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dagan-2001">
<DESCRIPTION>
<P>Study protocol is not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>Prespecified outcomes (primary and secondary) are listed in ClinicalTrials.gov (although uploaded after study end)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fireman-2003">
<DESCRIPTION>
<P>Study protocol is not available but trial includes all expected outcomes (including OM visits, frequent OM, tube procedures and Ab prescriptions)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jansen-2008">
<DESCRIPTION>
<P>Prespecified outcomes (primary and secondary) are listed in ClinicalTrials.gov</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>Prespecified outcomes (primary and secondary) are listed in ClinicalTrials.gov (although uploaded after study end)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 04:53:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2008">
<DESCRIPTION>
<P>Study design was described extensively in <LINK REF="REF-Moulton-2001" TYPE="REFERENCE">Moulton 2001</LINK> and <LINK REF="REF-O_x0027_Brien-2003" TYPE="REFERENCE">O'Brien 2003</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palmu-2009">
<DESCRIPTION>
<P>Prespecified outcomes (primary and secondary) are listed in ClinicalTrials.gov (although uploaded after study end)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prymula-2006">
<DESCRIPTION>
<P>Prespecified outcomes (primary and secondary) are listed in ClinicalTrials.gov</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-15 00:01:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Kempen-2006">
<DESCRIPTION>
<P>No study protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-20 04:24:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veenhoven-2003">
<DESCRIPTION>
<P>No study protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>Control group was vaccinated against MenC disease, but meningococci are not a causative pathogen in otitis media. Study enrolment was stopped as a result of prespecified interim analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dagan-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fireman-2003">
<DESCRIPTION>
<P>Control group was vaccinated against MenC disease, but meningococci are not a causative pathogen in otitis media. Study enrolment was stopped as a result of prespecified interim analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jansen-2008">
<DESCRIPTION>
<P>Co-administered with influenza vaccine in influenza season. Pivotal role of influenza viruses acknowledged by the authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:14:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>Mixed schedule with 187 children boosted with PPV-23. How was it known that only the children allocated to PCV7 OMPC should receive PPV-23 after November 1997?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2008">
<DESCRIPTION>
<P>Study enrolment was stopped as a result of prespecified interim analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-20 06:15:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palmu-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prymula-2006">
<DESCRIPTION>
<P>Study enrolment was stopped as a result of prespecified interim analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Kempen-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 07:33:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veenhoven-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-03-21 01:18:49 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-10-04 22:29:44 +1000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TD COLSPAN="5" VALIGN="BOTTOM">
<P>
<B>Pneumococcal conjugate vaccine compared with control intervention for preventing acute otitis media</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5" VALIGN="BOTTOM">
<P>
<B>Patient or population: </B>children aged 12 years or younger and a follow-up after vaccinations of at least 6 months</P>
<P>
<B>Settings: </B>open population</P>
<P>
<B>Intervention: </B>multivalent PCVs</P>
<P>
<B>Comparison: </B>control treatment</P>
</TD>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH VALIGN="BOTTOM">
<P>VE - relative effect (95% CI)*</P>
</TH>
<TH VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Frequency of all-cause AOM</B>
</P>
<P>
<I>PCV7 administered in early infancy</I>
</P>
<P>Follow-up 6 to 42 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RRR: -5% to 7%</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42,140 (4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Results are derived from 1 very large trial (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>/<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>) and 3 trials of approximately equal size (944 to 1666 participants) (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>)</P>
<P>Lowest efficacy was found in high-risk children (<LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>)<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Frequency of all-cause AOM</B>
</P>
<P>
<I>PD-PCV11 administered in early infancy</I>
</P>
<P>Follow-up 27 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RRR 34%</B> (21 to 44)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4968 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Results derived from 1 high-quality trial (<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>)</P>
<P>Part of the effect may be related to the protein D to which the polysaccharides are conjugated in the vaccine PD-PCV11, demonstrated to reduce non-typeable <I>H. influenzae</I> by 35% (95% CI 2 to 57)</P>
<P>AOM incidence rate in control group was low compared to the other studies on the effect on PCV7 in infants and the absolute risk difference was small (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Frequency of all-cause AOM</B>
</P>
<P>
<I>CRM197-PCV9 administered in healthy toddlers</I>
</P>
<P>Follow-up 24 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RRR 17%</B> (-2 to 33)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>264 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Results derived from 1 trial of moderate methodological quality (<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>). Uncertainty about the effect size (statistically non-significant effect) and outcome measure (parent-reported OM)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Frequency of all-cause AOM</B>
</P>
<P>
<I>PCV7 administered in older children with a known history of AOM</I>
</P>
<P>Follow-up 6 to 26 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RRR -29% to 57%</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1054 (3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Results are derived from 2 high-quality trials (<LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>; <LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>) and 1 trial of moderate methodological quality (<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>). The 2 high-quality trials found no beneficial effect of PCV in preventing AOM recurrences, while the other trial found PCV7/TIV not to be superior to TIV/placebo in preventing AOM during the influenza season</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Frequency of pneumococcal AOM</B>
</P>
<P>
<I>PCV7 administered in early infancy</I>
</P>
<P>Follow-up 6 to 42 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RRR 20% to 34%</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1233 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Results are derived from 2 high-quality trials (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>/<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Frequency of pneumococcal AOM</B>
</P>
<P>
<I>PD-PCV11 administered in early infancy</I>
</P>
<P>Follow-up 27 months</P>
<P/>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RRR 52% </B>(37 to 63)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>281 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Results derived from 1 high-quality trial in which myringotomy was performed in all children (<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
<P>*Results include both ITT and PP results; 95% CI lacking in case of multiple studies (range of effect estimates presented as we refrained from pooling).</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>AOM: acute otitis media<BR/>CI: confidence interval<BR/>ITT: intention-to-treat<BR/>OM: otitis media<BR/>PCV: pneumococcal conjugate vaccine<BR/>PP: per-protocol<BR/>RRR: relative reduction in risk<BR/>TIV: trivalent inactivated influenza vaccine<BR/>VE: vaccine efficacy<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-03-21 00:50:33 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-03-21 00:47:27 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-11-15 21:24:10 +1000" MODIFIED_BY="[Empty name]">The effect of pneumococcal conjugate vaccination on all-cause acute otitis media episodes</TITLE>
<TABLE COLS="8" ROWS="14">
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>Intention-to-treat</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="4" VALIGN="BOTTOM">
<P>Per-protocol</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Episodes/person year</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="BOTTOM">
<P>VE expressed as relative reduction in risk (95% CI)</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Episodes/person year</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="BOTTOM">
<P>Incidence rate difference - episodes per person year (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="BOTTOM">
<P>VE expressed as relative reduction in risk (95% CI)</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Treatment</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Treatment</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Control</P>
</TH>
</TR>
<TR>
<TD COLSPAN="8" VALIGN="TOP">
<P>
<B>PCV administered in early infancy</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>
</P>
<P>
<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6% (4 to 9)</P>
<P>6% (4 to 8)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7% (4 to 10)</P>
<P>7% (4 to 9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.16</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.24</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-0.08 ~</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6% (-4 to 16)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-1% (-12 to 10)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0.08</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0.13</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-0.04 ~</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>34% (21 to 44)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>
<SUP>*</SUP>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.4</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.4</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-5% (-25 to 12)<SUP>#</SUP>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.3</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.3</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0.0 (-0.13 to 0.14)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0% (-21 to 17)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4" VALIGN="TOP">
<P>
<B>PCV administered at a later age</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0.66</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0.79</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-0.14 (-0.29 to 0.02)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>17% (-2 to 33)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-25% (-57 to 1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.1</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0.83</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0.27 ~</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-29% (-62 to -2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0.78</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0.67</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0.11 ~</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-16% (-96 to 31)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>57% (6 to 80)<SUP>^</SUP>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI: confidence interval; HBV: hepatitis B vaccine; PCV: pneumococcal conjugate vaccine; TIV: trivalent influenza vaccine; VE: vaccine efficacy.</P>
<P>
<SUP>*</SUP>Cluster-randomised trial.<BR/>
<SUP>#</SUP>Defined as primary efficacy analysis. Analysis not entirely according to intention-to-treat principle as 88/944 children were not included in analysis because of not meeting strict chart review criteria.<BR/>
<SUP>^</SUP>Index group: TIV/PCV7, control: HBV/placebo; VE TIV/placebo versus HBV/placebo: 71% (95% 30% to 88%), i.e. larger VE TIV/placebo versus HBV/placebo then TIV/PCV7 versus HBV/placebo.</P>
<P>~ 95% CI could not be calculated as person-time across treatment groups was not reported.</P>
<P>Note: negative values for VE expressed as relative reduction in risk represent an increase in the risk for AOM.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-03-21 00:49:26 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-04-29 22:56:17 +1000" MODIFIED_BY="[Empty name]">The effect of pneumococcal conjugate vaccination on pneumococcal acute otitis media</TITLE>
<TABLE COLS="9" ROWS="14">
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4" VALIGN="BOTTOM">
<P>Intention-to-treat</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="4" VALIGN="BOTTOM">
<P>Per-protocol</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4" VALIGN="BOTTOM">
<P>VE expressed as relative reduction in risk (95% CI)</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="4" VALIGN="BOTTOM">
<P>VE expressed as relative reduction in risk (95% CI)</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Pneumococcal</P>
<P>AOM</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Vaccine-type</P>
<P>AOM</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Cross-reactive type AOM</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Non-vaccine-type AOM</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Pneumococcal</P>
<P>AOM</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Vaccine-type</P>
<P>AOM</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Cross-reactive type AOM</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Non-vaccine-type AOM</P>
</TH>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<B>PCV administered in infancy</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>
<SUP>#</SUP>
</P>
<P>
<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>65% P = 0.04</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>67% P = 0.08</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>
</P>
<P>
<LINK REF="STD-Palmu-2009" TYPE="STUDY">Palmu 2009</LINK> <SUP>^</SUP>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>54% (41 to 64)</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>34% (21 to 45)</P>
<P>20% (7 to 31)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>57% (44 to 67)</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>51% (27 to 67)</P>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-33% (-80 to 1)</P>
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>25% (11 to 37)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>56% (44 to 66)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-5% (-47 to 25)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-27% (-70 to 6)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>52% (37 to 63)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>58% (41 to 69)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>66% (22 to 85)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9% (-64 to 49)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK> <SUP>* #</SUP>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>64% (-34 to 90)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<B>PCV administered at a later age</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>34% P = 0.22</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>52% P = 0.21</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>21% P = 0.44</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>VE: vaccine efficacy; PCV: pneumococcal conjugate vaccine; MEF: middle ear fluid.<BR/>
<SUP>*</SUP>Cluster-randomised trial.<BR/>
<SUP>#</SUP>MEF collected from spontaneous draining ears; in the other studies MEF was routinely collected during AOM episodes through paracentesis.<BR/>
<SUP>^</SUP>Additional analysis of <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> including pneumococcal AOM by a positive culture or PCR.<BR/>Note: negative values represent an increase in the risk of AOM.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2014-03-21 00:50:33 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-04-29 23:15:01 +1000" MODIFIED_BY="[Empty name]">The effect of pneumococcal conjugate vaccination on recurrent acute otitis media</TITLE>
<TABLE COLS="3" ROWS="13">
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Intention-to-treat</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Per-protocol</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>VE expressed as relative reduction in risk (95% CI)</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>VE expressed as relative reduction in risk (95% CI)</P>
</TH>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>PCV administered in infancy</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>
</P>
<P>
<LINK REF="STD-Fireman-2003" TYPE="STUDY">Fireman 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>9% (4 to 14)</P>
<P>10% (7 to 13)</P>
</TD>
<TD ALIGN="CENTER">
<P>9% (3 to 15)</P>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>9% (-12 to 27)</P>
</TD>
<TD ALIGN="CENTER">
<P>16% (-6 to 35)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Prymula-2006" TYPE="STUDY">Prymula 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>56% (-2 to 81)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-O_x0027_Brien-2008" TYPE="STUDY">O'Brien 2008</LINK>
<SUP>*</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>PCV administered at a later age</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dagan-2001" TYPE="STUDY">Dagan 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Veenhoven-2003" TYPE="STUDY">Veenhoven 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Van-Kempen-2006" TYPE="STUDY">Van Kempen 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jansen-2008" TYPE="STUDY">Jansen 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>PCV: pneumococcal conjugate vaccine; VE: vaccine efficacy.<BR/>
<SUP>*</SUP>Cluster-randomised trial.<BR/>Note: negative values represent an increase in the risk of recurrent AOM.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-09-07 01:29:51 +1000" MODIFIED_BY="[Empty name]"/>
<FIGURES MODIFIED="2014-03-24 21:50:13 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-03-24 21:50:13 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-03-24 21:50:13 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVEAAAKfCAIAAABYHmxMAAAedklEQVR42u3dv44lR93G8ZGQEMEG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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-12-09 10:43:10 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-11-27 14:34:28 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-08-12 16:43:13 +1000" MODIFIED_BY="[Empty name]">Previous search</TITLE>
<APPENDIX_BODY MODIFIED="2013-11-27 14:34:28 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2007, issue 2), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (January 1995 to November 2007); and EMBASE (January 1995 to November 2007).</P>
<P>We used the following search strategy for searching MEDLINE and CENTRAL and modified terms for searching EMBASE.</P>
<SUBSECTION>
<HEADING LEVEL="4">MEDLINE</HEADING>
<P>#1 explode &#8216;bacterial-vaccine&#8217; / all subheadings<BR/>#2 explode &#8216;bacterial AND vaccine&#8217; / all subheadings<BR/>#3 explode &#8216;Pneumococcus-vaccine&#8217; / all subheadings<BR/>#4 pneumococc* near immunity*<BR/>#5 pneumococc* near vaccin*<BR/>#6 #1 or #2 or #3 or #4 or #5<BR/>#7 explode &#8216;otitis media&#8217; / all subheadings<BR/>#8 (otitis media in ti) or (otitis media in ab)<BR/>#9 #7 or #8<BR/>#10 #6 or #9<BR/>#11 explode &#8216;randomised-controlled-trial&#8217; / all subheadings<BR/>#12 explode &#8216;controlled-study&#8217; / all subheadings<BR/>#13 explode &#8216;randomisation&#8217; / all subheadings<BR/>#14 explode &#8216;single-blind-procedure&#8217; / all subheadings<BR/>#15 explode &#8216;double-blind-procedure&#8217; / all subheadings<BR/>#16 explode &#8216;crossover-procedure&#8217; / all subheadings<BR/>#17 explode &#8216;phase-3-clinical-trial&#8217; / all subheadings<BR/>#18 (control* near trial*) in ti)<BR/>#19 (control* near trial*) in ab)<BR/>#20 (singl* or doubl* or trebl* or tripl*) near ((blind* or mask*) in ti)<BR/>#21 (singl* or doubl* or trebl* or tripl*) near ((blind* or mask*) in ab)<BR/>#22 random* near ((allocat* or assign*) in ti)<BR/>#23 random* near ((alsocat* or assign*) in ab)<BR/>#24 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23<BR/>#25 #10 and #24</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-02-08 10:55:37 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-08-12 16:52:34 +1000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-02-08 10:55:37 +1000" MODIFIED_BY="[Empty name]">
<P>#14. #9 AND #13 <BR/>#13. #10 OR #11 OR #12 <BR/>#12. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR 'cross-over':ab,ti OR volunteer*:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1 blind*):ab,ti <BR/>#11. 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp <BR/>#10. 'randomized controlled trial'/exp <BR/>#9. #3 AND #8 <BR/>#8. #4 OR #5 OR #6 OR #7 <BR/>#7. pcv*:ab,ti <BR/>#6. (pneumococc* NEAR/5 (vaccin* OR conjugat* OR immuni*)):ab,ti <BR/>#5. 'bacterial vaccine'/de <BR/>#4. 'pneumococcus vaccine'/de <BR/>#3. #1 OR #2 <BR/>#2. 'otitis media':ab,ti OR aom:ab,ti <BR/>#1. 'otitis media'/exp </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-02-08 10:56:47 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-08-12 16:54:59 +1000" MODIFIED_BY="[Empty name]">CINAHL (Ebsco) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-02-08 10:56:47 +1000" MODIFIED_BY="[Empty name]">
<P>S22 S11 and S20 <BR/>S21 S11 and S20 <BR/>S20 S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 <BR/>S19 (MH "Quantitative Studies") <BR/>S18 (MH "Placebos") <BR/>S17 TI placebo* OR AB placebo* <BR/>S16 TI random* OR AB random* <BR/>S15 TI ( singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask* ) OR AB (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask* ) <BR/>S14 TI clinic* trial* OR AB clinic* trial* <BR/>S13 PT clinical trial <BR/>S12 (MH "Clinical Trials+") <BR/>S11 S3 and S10 <BR/>S10 S4 or S5 or S6 or S7 or S8 or S9 <BR/>S9 TI pcv* OR AB pcv* <BR/>S8 TI pneumococc* N5 immuni* OR AB pneumococc* N5 immuni* <BR/>S7 TI pneumococc* N5 conjugat* OR AB pneumococc* N5 conjugat* <BR/>S6 TI pneumococc* N5 vaccin* OR AB pneumococc* N5 vaccin* <BR/>S5 (MH "Bacterial Vaccines") <BR/>S4 (MH "Pneumococcal Vaccine") <BR/>S3 S1 or S2 <BR/>S2 TI ( otitis media or aom ) OR AB ( otitis media or aom ) <BR/>S1 (MH "Otitis Media+") </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-02-08 10:57:19 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-08-12 17:00:33 +1000" MODIFIED_BY="[Empty name]">LILACS (Brieme) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-02-08 10:57:19 +1000" MODIFIED_BY="[Empty name]">
<P>(mh:"otitis media" OR "otitis media" OR "Otite Mdia" OR mh:c09.218.705.663* OR aom) AND (mh:"Pneumococcal Vaccines" OR "Vacunas Neumococicas" OR "Vacinas Pneumoccicas" OR mh:"Vaccines, Conjugate" OR "Vacunas Conjugadas" OR "Vacinas Conjugadas" OR mh:"Bacterial Vaccines" OR "Vacunas Bacterianas" OR "Vacinas Bacterianas" OR "pneumococcal vaccine" OR "pneumococcal vaccines" OR "conjugate vaccines" OR "conjugate vaccine" OR pcv*) AND db:("LILACS") AND type_of_study:("clinical_trials")</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-12-09 10:43:10 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-08-12 17:01:23 +1000" MODIFIED_BY="[Empty name]">Web of Science (Thomson ISI) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-09 10:43:10 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="6">
<TR>
<TD VALIGN="TOP">
<P># 6</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=10&amp;SID=P2ojp4dcifLIej@H@fj&amp;search_mode=Refine">40</A>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>#4 AND #3</P>
<P>Refined by: Publication Years=( 2011 OR 2012 OR 2013 )</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 5</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=9&amp;SID=P2ojp4dcifLIej@H@fj&amp;search_mode=CombineSearches">205</A>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>#4 AND #3</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 4</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=4&amp;SID=P2ojp4dcifLIej@H@fj&amp;search_mode=GeneralSearch">1,334,537</A>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Topic=(random* or placebo* or allocat* or crossover* or "cross over" or ((doubl* or singl*) NEAR/1 (blind* or mask*))) OR Title=(trial)</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 3</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=8&amp;SID=P2ojp4dcifLIej@H@fj&amp;search_mode=CombineSearches">1,095</A>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>#2 AND #1</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 2</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=2&amp;SID=P2ojp4dcifLIej@H@fj&amp;search_mode=GeneralSearch">11,997</A>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Topic=(pneumococc* NEAR/5 (vaccin* or conjugat* or immuni*)) OR Topic=(pcv*)</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 1</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=7&amp;SID=P2ojp4dcifLIej@H@fj&amp;search_mode=AdvancedSearch">17,113</A>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>TS=("otitis media" or aom)</P>
<P>
<I>Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=All Years</I>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>